

12 Reel PCT/PTO 17 JUL 1998

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

GRONHOJ-LARSEN=2

U.S. APPLICATION NO. (If known, see 37 CFR 1.5

09/101825

INTERNATIONAL APPLICATION NO. PCT/DK97/00021	INTERNATIONAL FILING DATE 16 January 1997	PRIORITY DATE CLAIMED 18 January 1996
TITLE OF INVENTION SYNTHETIC IL-10 ANALOGUES		
APPLICANT(S) FOR DO/EO/US Christian GRONHOJ-LARSEN		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none">a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none">a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).b. <input type="checkbox"/> have been transmitted by the International Bureau.c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input checked="" type="checkbox"/> have not been made and will not be made.8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).10. <input type="checkbox"/> A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
Items 11. to 16. below concern document(s) or information included:		
<ol style="list-style-type: none">11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.14. <input type="checkbox"/> A substitute specification.15. <input type="checkbox"/> A change of power of attorney and/or address letter.16. <input checked="" type="checkbox"/> Other items or information:<ol style="list-style-type: none">1. A courtesy copy of the specification as originally filed.2. A small entity statement - small business concern.3. A courtesy copy of the first page of the International Publication (WO97/26279).4. A courtesy copy of the International Search Report.5. A courtesy copy of the International Preliminary Examination Report with annexes. <u>Note: Please use the specification pages and the claims as they appear in the IPER annexes in place of the corresponding specification pages and original claims for examination in this case.</u>6. Formal drawings, 14 sheets, figures 1-14.		

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO. PCT/DK97/00021		ATTORNEY'S DOCKET NUMBER GRONHOJ-LARSEN=2	
---	--	--	--	---	--

17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1070.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$930.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$790.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$720.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$98.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
				\$ 930.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$ claims fees not submitted	
Total claims	17 - 20 =		x \$22.00	\$	
Independent claims	8 - 3 =		x \$82.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$ 930.00	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$ - 465.00	
SUBTOTAL =				\$ 465.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
(BASIC) TOTAL NATIONAL FEE =				\$ 465.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$ 465.00	
				Amount to be refunded:	\$
				charged:	\$

a. ☒ A check in the amount of \$ 465.00 to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
 A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any deficiency in the basic national ^{fee only,} or credit any
 overpayment to Deposit Account No. 02-4035. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

BROWDY AND NEIMARK, P.L.L.C.
 419 Seventh Street N.W., Suite 300
 Washington, D.C. 20004


 SIGNATURE
Iver P. Cooper

NAME
28,005

REGISTRATION NUMBER

Date of this submission: July 17, 1998

Applicant or Patentee: _____ Case Docket No. GRONHOJ-LARSEN=2
Serial or Patent No.: _____
Filed or Issued: _____
For: Synthetic IL-10 Analogues (Nat'l Phase of PCT/DK97/00021)

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN

I hereby declare that I am

- ☐ the owner of the small business concern identified below.
☒ an official of the small business concern empowered to act on behalf of the concern identified below.

NAME OF CONCERN Steen Research Group A/S
ADDRESS OF CONCERN Dunbirkevej 6, DK-5250 Odense SV, Denmark

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled Synthetic IL-10 Analogues

by inventor (s) Christian Grønhøj Larsen and Borbala Gesser described in

- ☐ the specification filed herewith
☐ application serial no. _____, filed _____
☐ patent no. _____, issued _____

If the right held by the above identified small business concern is not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).


FULL NAME Connective Therapeutics
ADDRESS 3400 West Bayshore Road, Palo Alto, CA 94303, USA
☐ INDIVIDUAL ☒ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____
ADDRESS _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate.
(37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Steen Grasted Larsen
TITLE OF PERSON OTHER THAN OWNER Managing director
ADDRESS OF PERSON SIGNING _____

SIGNATURE  DATE 12/6 1998

418 Rec'd PCT/PTO 29 JAN 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: GRONHOJ-LARSEN, et al.
 Serial No.: 09/101,825
 Filed: July 17, 1998
 For: SYNTHETIC IL-10 ANALOGUES

Art Unit:
 Examiner:
 Washington, D.C.
 Atty.'s Docket: GRONHOJ-LARSEN=2
 Date: January 29, 1999

THE COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

Sir:

Transmitted herewith is an ☐ Amendment ☒ Second Preliminary Amendment

in
 the above-identified application.

☒ Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.

☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

☐ No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		Small Entity		Other Than a Small Entity	
	Claims Remaining After Amendment		Highest No Previously Paid For		Present Extra		Rate		Additional Fee
Total	31	Minus	20	=11		x 9	\$99.00	x18	\$
Indep.	3	Minus	3	= 0		x39	\$	x78	\$
First Presentation of Multiple Dependent Claim						+130	\$	+260	\$
TOTAL ADDITIONAL CLAIMS FEE							\$99.00	Total	\$

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- ☐ First - \$ 55.00
☐ Second - \$190.00
☐ Third - \$435.00
☐ Fourth - \$680.00

Other Than Small Entity

Response Filed Within

- ☐ First - \$ 110.00
☐ Second - \$ 380.00
☐ Third - \$ 870.00
☐ Fourth - \$1360.00

99.00 0P

☐ Less fees (\$) already paid for months extension of time on


☐ Please charge my Deposit Account No. 02-4035 in the amount of \$. A duplicate copy of this sheet is attached.

☒ A check in the amount of \$99.00 is attached (check no. 21305).

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK
 Attorneys for Applicant(s)

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197

By: 
 IVER P. COOPER
 Registration No. 28,005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Art Unit:
GRONHOJ-LARSEN, et al.) Examiner:
Serial No.: 09/101,825) Washington, D.C.
Filed: July 17, 1998) January 29, 1999
For: SYNTHETIC IL-10) Docket No.: GRONHOJ-LARSEN=2
ANALOGUES)

SECOND PRELIMINARY AMENDMENT

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

S i r :

Prior to action on the merits, please amend as follows:

IN THE CLAIMS

Please cancel claims 1-17.

Please add the following new claims:

--18. A polypeptide amounting in total up to about 100 amino acids which comprises the following sequence

Thr-X₄-Lys-X₅-Arg-X₆ (SEQ ID NO:19),

wherein

X₄ and X₅ are independently selected from the group consisting of Met, Ile, Leu and Val; and

X₆ is selected from the group consisting of Asn, Asp, Gln and Glu,

wherein at least one of the following conditions (I)-(V) is true:

I) at least one of X₄, X₅, X₆, Thr, Lys, and Arg is independently substituted with a non-natural or unusual amino acid,

II) the polypeptide is cyclized,

III) the polypeptide is stabilized,

IV) the aminoterminal amino acid residue is acylated, or

V) the carboxyterminal amino acid residue is amidated,

said polypeptide having at least one of the following properties:

- a) induces inhibition of spontaneous IL-8 production by human monocytes,
- b) induces inhibition of IL-1 β induced IL-8 production by human peripheral blood mononuclear cells (PBMC),
- c) induces production of interleukin-1 receptor antagonistic protein (IRAP) by human monocytes,
- d) induces chemotactic migration of CD8+ human T lymphocytes in vitro,
- e) desensitizes human CD8+ T cells resulting in an unresponsiveness towards rhIL-10,
- f) suppresses the chemotactic response of CD4+ T human lymphocytes towards IL-8,
- g) suppresses the chemotactic response of human monocytes towards MCAF/MCP-1,
- h) inhibits class II MHC molecule expression on human monocytes stimulated by IFN- γ ,
- i) induces the production of IL-4 by cultured normal human CD4+ T cells,
- j) reduces the TNF α production in human mixed leukocyte reaction, or
- k) downregulates TNF α and IL-8 production in a rabbit model of bile acid induced acute pancreatitis and reduces neutrophil infiltration in the lungs of the treated rabbits.

19. A polypeptide according to claim 18, which comprises the following sequence

X_3 -Thr- X_4 -Lys- X_5 -Arg- X_6 (SEQ ID NO:20),

wherein

X_3 , X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and

X_6 is selected from the group consisting of Asn, Asp, Gln and Glu,

wherein at least one of the following conditions (I)-(V) is true:

I) at least one of X_3 , X_4 , X_5 , X_6 , Thr, Lys, and Arg is independently substituted with a non-natural or unusual amino acid,

II) the polypeptide is cyclized,

III) the polypeptide is stabilized,

IV) the aminoterminal amino acid residue is acylated, or

V) the carboxyterminal amino acid residue is amidated.

20. A polypeptide according to claim 18, which comprises the following sequence

X_2 - X_3 -Thr- X_4 -Lys- X_5 -Arg- X_6 (SEQ ID NO:21),

wherein

X_2 is Tyr or Phe,

X_3 , X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and

X_6 is selected from the group consisting of Asn, Asp, Gln and Glu,

wherein at least one of the following conditions (I)-(V) is true:

I) at least one of X_2 , X_3 , X_4 , X_5 , X_6 , Thr, Lys, and Arg is independently substituted with a non-natural or unusual amino acid,

II) the polypeptide is cyclized,

III) the polypeptide is stabilized,

IV) the aminoterminal amino acid residue is acylated, or

V) the carboxyterminal amino acid residue is amidated.

21. A polypeptide according to claim 18, which comprises the following sequence

X_1 - X_2 - X_3 -Thr- X_4 -Lys- X_5 -Arg- X_6 (SEQ ID NO:22),

wherein

X_1 is Ala or Gly,

X_2 is Tyr or Phe,

X_3 , X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and

X_6 is selected from the group consisting of Asn, Asp, Gln and

Glu,

wherein at least one of the following conditions (I)-(V) is true:

I) at least one of X_1 , X_2 , X_3 , X_4 , X_5 , X_6 , Thr, Lys, and Arg is independently substituted with a non-natural or unusual amino acid,

II) the polypeptide is cyclized,

III) the polypeptide is stabilized,

IV) the aminoterminal amino acid residue is acylated, or

V) the carboxyterminal amino acid residue is amidated.

22. A polypeptide amounting up to about 30 amino acids which comprises the following sequence

Thr- X_4 -Lys- X_5 -Arg- X_6 (SEQ ID NO:19),

wherein

X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and

X_6 is selected from the group consisting of Asn, Asp, Gln and Glu,

wherein

at least one of Thr, Lys, and Arg is independently substituted with a non-natural or unusual amino acid, said polypeptide having at least one of the properties defined in claim 18.

23. A polypeptide according to claim 18 amounting up to 30 amino acids.

24. A polypeptide according to claim 18 amounting up to 20 amino acids.

25. A polypeptide according to claim 18 amounting up to 15 amino acids.

26. A polypeptide according to claim 18 amounting in total 10, 11, 12, 13, or 14 amino acids.

27. A polypeptide according to claim 18 amounting in total 9 amino acids.

28. The polypeptide of claim 21 wherein at least condition

(I) is true.

29. The polypeptide of claim 20 wherein at least condition (I) is true.

30. The polypeptide of claim 19 wherein at least condition (I) is true.

31. The polypeptide of claim 18 wherein at least condition (I) is true.

32. The polypeptide of claim 18 which has the amino acid sequence Ala-Tyr-Met-Thr-Met-Lys-Ile-Arg-Asn (SEQ ID NO:1).

33. A substance which is a polypeptide as defined in claim 18 or is a salt, ester, or a solvate of said polypeptide.

34. A polypeptide according to claim 18 which is cyclized.

35. A polypeptide according to claim 18 which is stabilized.

36. A polypeptide according to claim 18 wherein the aminoterminal amino acid residue is acylated.

37. A polypeptide according to claim 18 wherein the carboxyterminal amino acid residue is amidated.

38. A polypeptide according to claim 18 encapsulated in a liposome.

39. A polypeptide according to claim 18 in substantially pure form.


40. A peptidomimetic modelled on the basis of a polypeptide according to claim 18.

41. A pharmaceutical composition comprising a polypeptide according to claim 18, or a salt, ester or solvate of said polypeptide, or a peptidomimetic modelled on the basis of said polypeptide.

42. A method of treating and/or preventing one or more of the diseases selected from the group consisting of pre-term labour caused by infection or other conditions, rheumatoid arthritis, Lyme's arthritis, gout, sepsis syndrome, hyperthermia, ulcerative colitis or enterocolitis, osteoporosis, cytomegalovirus, periodontal diseases, glomerulonephritis, chronic, non-

infectious inflammation of the lung (e.g. sarcoidosis and smoker's lung), granuloma formation, fibrosis of the liver, fibrosis of the lung, transplant rejection, graft vs. host disease, chronic myeloid leukemia, acute myeloid leukemia, other neoplastic diseases, asthma bronchiale, diabetes mellitus, type I (insulin dependent), arteriosclerosis/atherosclerosis, psoriasis, chronic B lymphocyte leukemia, common variable immunodeficiency, side-effects using other biological response modifiers, disseminated intravascular coagulation, systemic sclerosis, encephalomyelitis, lung inflammation, hyper IgE syndrome, enterocolitis, cancer metastasis and growth, adoptive immune therapy, acquired respiratory distress syndrome, sepsis, reperfusion syndrome, postsurgical inflammation, organ transplantation, alopecia, and pancreatitis, the method comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a pharmaceutical composition according to claim 41.

43. A method of treating and/or preventing pancreatitis, the method comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of (1) a polypeptide amounting at most 100 amino acids which comprises the following formula



wherein

X₄ and X₅ are independently selected from the group consisting of Met, Ile, Leu and Val; and

X₆ is selected from the group consisting of Asn, Asp, Gln and Glu,

or (2) of a peptidomimetic modelled on the basis of the above formula.

44. A method of treating and/or preventing acquired immunodeficiency syndrom (AIDS/HIV), cutaneous HPV-infection, or spontaneous abortion, the method comprising administering to a

patient in need thereof a therapeutically or prophylactically effective amount

1) of a polypeptide amounting at most 100 amino acids which comprises the following formula

Thr-X₄-Lys-X₅-Arg-X₆ (SEQ ID NO:19),

wherein

X₄ and X₅ are independently selected from the group consisting of Met, Ile, Leu and Val; and

X₆ is selected from the group consisting of Asn, Asp, Gln and Glu,

or

2) of a peptidomimetic modelled on the basis of the above formula.

45. A method of treating and/or preventing pancreatitis, the method comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a polypeptide amounting at most 100 amino acids, said polypeptide comprising the formula

Thr-X₄-Lys-X₅-Arg-X₆ (SEQ ID NO:19),

wherein

X₄ and X₅ are independently selected from the group consisting of Met, Ile, Leu and Val; and

X₆ is selected from the group consisting of Asn, Asp, Gln and Glu,

said polypeptide having at least one of the properties defined in claim 18.

46. A method of treating and/or preventing pancreatitis, the method comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of (1) a polypeptide according to claim 18 said polypeptide comprising an amino acid sequence selected from the group consisting of

X₁-X₂-X₃-Thr-X₄-Lys-X₅-Arg-X₆ (SEQ ID NO:22),

X₂-X₃-Thr-X₄-Lys-X₅-Arg-X₆ (SEQ ID NO:21),

X_3 -Thr- X_4 -Lys- X_5 -Arg- X_6 (SEQ ID NO:20),

wherein

X_1 is Ala or Gly,

X_2 is Tyr or Phe,

X_3 , X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu, and Val; and

X_6 is selected from the group consisting of Asn, Asp, Gln, and Glu,

(2) of a peptidomimetic modelled on the basis of one of the above formula.

47. A process for synthesizing of a polypeptide according to claim 18 by use of solid-phase peptide synthesis (SPPS), the process comprising the following steps:

a) covalently coupling the carboxy-terminal amino acid in the form of an N-alpha-protected, optionally side chain-protected reactive derivative, either directly or by means of a suitable linker to a solid support,

b) removing the N-alpha-protective group,

c) adding the succeeding protected amino acids according to the desired sequence in a stepwise manner,

d) removing the side chain-protective groups, if any, and

e) upon or after assembly of the complete peptide chain, cleaving the peptide from the resin.

48. A polypeptide according to claim 18, or a polypeptide amounting at most 100 amino acids which comprises the following formula

Thr- X_4 -Lys- X_5 -Arg- X_6 (SEQ ID NO:19),

wherein

X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and

X_6 is selected from the group consisting of Asn, Asp, Gln and Glu,

wherein

USSN - 09/101,825

the binding affinity of the polypeptide for the IL-10 receptor is increased or decreased compared to a polypeptide having the amino acid sequence Ala-Tyr-Met-Thr-Met-Lys-Ile-Arg-Asn (SEQ ID NO:1).--

REMARKS

These amendments put the claims in better condition for allowance.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: 

Iver P. Cooper
Reg. No. 28,005

419 Seventh Street, N.W.
Washington, D.C. 20004
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:lms
f:\user19\wp\n-q\gro825us.pre

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit:
)	
Christian GRONHOJ-LARSEN)	
)	
IA No.: PCT/DK97/00021)	
)	Washington, D.C.
IA Filed: January 16, 1997)	
)	
U.S. App. No.:)	
(Not Yet Assigned))	July 17, 1998
)	
National Filing Date:)	
(Not Yet Received))	
)	
For: SYNTHETIC IL-10 ANALOGUES)	Docket No.: GRONHOJ-LARSEN=2

PRELIMINARY AMENDMENT

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

Contemporaneous with the filing of this case and prior
to calculation of the filing fee, kindly amend as follows:

IN THE CLAIMS

Claim 8, line 1, delete "any of claims 4-7", and insert
therefor --claim 4--.

Claim 9, line 1, delete "any of claims 4-7", and insert
therefor --claim 4--.

Claim 10, line 1, delete "any of claims 4-7", and insert
therefor --claim 4--.

Claim 11, line 1, delete "any of claims 4-7", and insert
therefor --claim 4--.

Claim 13, line 2, delete "any of claims 4-12", and
insert therefor --claim 4--.

Claim 14, lines 1 and 2, delete "any of claims 4-12",
and insert therefor --claim 4--.

In re of GRONHOJ-LARSEN=2

Claim 15, line 1, delete "claim 4-12", and insert therefor --claim 4--.

Claim 16, line 5, delete "any of claims 4-12", and insert therefor --claim 4--.

Claim 17, lines 1 and 2, delete "any of claims 4-12", and insert therefor --claim 4--.

If, inadvertently, a proper multiple dependent claim has not been amended to reduce it to single dependency, please amend it to be dependent solely on the first-mentioned claim, or, if that is not possible, please cancel the claim and notify the undersigned.

REMARKS

The above amendments to the claims are being made in order to eliminate any properly multiply dependent claims, for the purpose of reducing the filing fee. Please enter this amendment prior to calculation of the filing fee in this case.

Favorable consideration and allowance are earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By


Iver P. Cooper
Registration No. 28,005

IPC:bcs
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528

f:\user3\98jul\gro2.pa

SYNTHETIC IL-10 ANALOGUES

FIELD OF INVENTION


The present invention relates to the pharmaceutical use of substances which are interleukin 10 (IL-10) agonists. In particular, the invention relates to the use of a substance of the invention for the manufacture of a pharmaceutical composition for the reduction of TNF α production and/or the prophylaxis or treatment of pancreatitis, arthritis urica (gout), allergy of the skin, allergic reactions in the skin, tissue damage as a result of hypoxia/ischemia (infarction, reperfusion), inflammatory reactions due to virus infections, and/or for the manufacture of a conceptive agent.

BACKGROUND OF THE INVENTION

Pharmaceutical compositions comprising hIL-10 or vIL-10, and the use of hIL-10 or vIL-10 for the manufacture of a pharmaceutical composition for the treatment of various conditions have been disclosed in e.g. WO 93/02693 and WO 94/04180, and certain IL-10 agonists have been disclosed in WO 96/01318.

SUMMARY OF THE INVENTION

The present invention relates to the use of a substance or polypeptide according to the formula




wherein

X_1 is Ala or Gly,
 X_2 is Tyr or Phe,
 X_3 , X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and
 X_6 is selected from the group consisting of Asp, Gln and Glu,

optionally at least one of X_1 , X_2 , X_3 , X_4 , X_5 and X_6 is independently substituted with non-natural or unusual amino acids and/or the peptide is cyclized and/or the peptide is stabilized and/or the amino terminal amino acid residue is acylated and/or the carboxy terminal amino acid residue is amidated, and peptidomimetics modelled on the basis of the above formula for the preparation of a pharmaceutical composition for the reduction of TNF α production and/or for the prophylaxis or treatment of pancreatitis.

- 10 Further, the invention relates to a substance or polypeptide having the formula



wherein

X_1 is Ala or Gly,

- 15 X_2 is Tyr or Phe,

X_3 , X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and

X_6 is selected from the group consisting of ^{Asn,} Asp, Gln and Glu,

- wherein at least one of X_1 , X_2 , X_3 , X_4 , X_5 and X_6 is independently substituted with non-natural or unusual amino acids and/or the peptide is cyclized and/or the peptide is stabilized and/or the amino terminal amino acid residue is acylated and/or the carboxy terminal amino acid residue is amidated, and peptidomimetics modelled on the basis of the above formula, said substance or polypeptide having at least one of the following properties:
- 20
- 25

- a) induces inhibition of spontaneous IL-8 production by human monocytes,
- b) induces inhibition of IL-1 β induced IL-8 production by human peripheral blood mononuclear cells (PBMC),
- 30 c) induces production of interleukin-1 receptor antagonistic protein (IRAP) by human monocytes,

- d) induces chemotactic migration of CD8+ human T lymphocytes *in vitro*,
- e) desensitizes human CD8+ T cells resulting in an unresponsiveness towards rhIL-10,
- 5 f) suppresses the chemotactic response of CD4+ human T lymphocytes towards IL-8,
- g) suppresses the chemotactic response of human monocytes towards MCAF/MCP-1,
- h) inhibits class II MHC molecule expression on human monocytes stimulated with IFN- γ ,
- 10 i) induces the production of IL-4 by cultured normal human CD4+ T cells,
- j) reduces the TNF α production in human mixed leukocyte reaction,
- 15 k) downregulates TNF α and IL-8 production in a rabbit model of bile acid induced acute pancreatitis and reduces neutrophil infiltration in the lungs of the treated rabbits.

It is contemplated (as described in detail in the following description of immunological mechanisms) that the action mechanism is via interference with the action of mediators of the immune system, in particular cytokines such as monokines, lymphokines, chemokines and monokine-receptor antagonists, i.e. that the substance of the invention interferes with/suppresses the production and/or action of certain cytokines and thus inhibits pathological processes leading to tissue damage, and that the substance of the invention induces the production of natural monokine-receptor antagonists thus interfering with/suppressing the action of certain cytokines such as TNF α or IL-1 and thereby inhibiting pathological processes which lead to tissue damage.

An important embodiment of the present invention thus relates to a pharmaceutical composition comprising, as the active ingredient, a substance of the invention.

In a further aspect, the present invention relates to the use of a substance of the invention for the manufacture of a pharmaceutical composition for substantially inhibiting a biological effect related to a cytokine, i.e. the use of a substance of the invention as an IL-1 receptor antagonist protein/peptide, lymphokine, monokine, interleukin, interferon, chemokine or colony-stimulating factor. Another aspect relates to the use of a substance of the invention for the manufacture of a pharmaceutical composition for the prophylaxis or treatment of a condition related to the disturbance of a cytokine system, i.e. the IL-1 receptor antagonist protein/peptide, lymphokine, monokine, interleukin, interferon, chemokine or colony-stimulating factor system. In another aspect, the invention also relates to a method of treating a condition in a human related to a disturbance in a cytokine system which method comprises administering to the subject an effective amount of a substance of the invention.

The cellular immune system takes part in the development of such disorders as infectious, inflammatory and neoplastic diseases. Immunocompetent cells and their products may play important roles in the initiation, progression and possible chronic nature of development of inflammatory conditions. These disorders are often without known etiology and includes common diseases such as diabetes mellitus, rheumatoid arthritis, inflammatory diseases of the gastro-intestinal tract and of the skin. Apart from these examples, cell-mediated immunity or pro-inflammatory mediators, however, contribute to many other inflammatory and proliferative diseases (see Table 1).

TABLE 1

Some diseases where macrophages/T-lymphocyte-mediated immune reactions are considered pathogenetically important

Skin diseases:

Psoriasis

Atopic dermatitis

Contact dermatitis
Cutaneous T cell lymphoma (CTCL)
Sezary syndrome
Pemphigus vulgaris
5 Bullous pemphigoid
Erythema nodosum
Scleroderma

Auto-immune (including rheumatic) diseases:

Uveitis

- 10 Bechet's disease
Sarcoidosis Boeck
Sjögren's syndrome
Rheumatoid arthritis
Juvenile arthritis
15 Reiter's syndrome
Gout
Osteoarthritis
Systemic lupus erythematosus
Polymyositis
20 Myocarditis
Primary biliary cirrhosis
Crohn's disease
Ulcerative colitis
Multiple sclerosis and other demyelinating diseases
25 Aplastic anaemia
Idiopathic thrombocytopenic purpura
Multiple myeloma and B cell lymphoma
Simmons' panhypopituitarism
Graves' disease and Graves' ophthalmopathy
30 Subacute thyreoditis and Hashimoto's disease
Addison's disease
Insulin-dependent diabetes mellitus (type 1)

Other diseases

- Various clinical syndromes with vasculitis (e.g. polyarteri-
35 tis nodosa, Wegener's granulomatosis, Giant cell arteritis
Fever, malaise

Anorexia (e.g. in acute and chronic inflammatory and infectious diseases)

Disseminated intravascular coagulation (DIC)

Arteriosclerosis (atherosclerosis)

5 Shock (e.g. in gram-negative sepsis)

Cachexia (e.g. in cancer, chronic infectious and chronic inflammatory diseases)

Transplant rejection and graft vs. host disease

Prevention of spontaneous abortion

10

IL-10 activity on cytokine production:

hIL-10 inhibits the production of a number of cytokines including interferon- γ (IFN- γ), Tumor Necrosis Factor- α (TNF- α), Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), Granulocyte-CSF (G-CSF), IL-1 α , IL-1 β , IL-2, IL-6, IL-8 and Monocyte Chemotactic polypeptide-1 (MCP-1/MCAF) by monocytes/macrophages and/or T lymphocytes (4, 5). IL-10 also inhibits the ability of monocytes to migrate as a response to the chemokine MCP-1/MCAF (75). Further, hIL-10 induces the production of an endogenous, natural interleukin-1 receptor antagonist (IRAP) (6), which inhibits IL-1 α and IL-1 β by competing with receptor binding. Since IL-8 is strongly inducible by IL-1 α and by IL-1 β , IL-10 exerts part of its inhibitory effect on IL-8 production by stimulating the production of the IL-1-receptor antagonist IRAP. This last mechanism is of considerable importance for the present invention as described and exemplified in the following. IRAP has anti-inflammatory activities (9), and its therapeutic effect in rheumatoid arthritis has been suggested (10). Also, IRAP proved to be effective in the treatment of sepsis syndrome and a dose-dependent, 28-day survival benefit was associated with IRAP treatment ($p = 0.015$) in a study by Fisher et al. (11). IRAP may exert parts of its anti-inflammatory effects by inhibiting chemokine-production such as the production of IL-8.

IL-10 and antigen expression:

IL-10 inhibits the expression of class II MHC expression on human monocytes (8). Constitutive and IL-4 or IFN- γ induced expression of HLA-DR/DP and DQ was inhibited by hIL-10 (12).

- 5 In addition, monocytes pre-incubated with IL-10 are refractory to subsequent induction of class II MHC expression by IL-4 or IFN- γ . IL-10 inhibits class II expression by human monocytes following activation by LPS (12, 76). BALB/c mice given 1 to 10 mg of IL-10 concomitantly with a lethal dose of
10 LPS were protected from death (6).

IL-10 inhibits nitrogen intermediates and superoxide anions. IL-10 also inhibits reactive nitrogen intermediate (NO) as well as reactive oxygen intermediates (H₂O₂) by macrophages following activation by IFN- γ (13).

IL-10 and T cell activity:

IL-10 has also modulatory effects on T cell functions/activity. Thus, hIL-10 is a potent chemotactic factor to CD8+ T lymphocytes, while hIL-10 does not show chemotaxis towards
20 CD4+ T cells (14). Additionally, IL-10 suppresses the capacity of CD4+ T cells to respond to the chemotactic signals of the β -chemokine RANTES as well as the α -chemokine IL-8. hIL-10 also directly inhibits the proliferation of human peripheral blood T cells and CD4+ T cell clones (14).

25 Therapeutic considerations:

- These *in vivo* results/data and other data summarized e.g. in WO 96/01318 strongly suggest a homeostatic role of IL-10 in controlling cell-mediated and monokine-amplified immune inflammation and indicate the wide-ranged therapeutical
30 applications of IL-10 or a drug with IL-10-like activity in the treatment of diseases which are characterized by a decreased/insufficient production and/or activity of IL-10.

Tables 1 and 2 list some diseases where an immune-modulator like IL-10 or an immune-modulator with IL-10-like activity is considered to have therapeutic importance:

TABLE 2

-
- 5 Some diseases where an immune-modulator with IL-10-like activity, due to its induction of IRAP production and/or inhibition of cytokine-production and/or activity may have therapeutic importance (ref. 20-74 + 109)
-
- 10 Pre-term labour caused by infection or other conditions
Rheumatoid arthritis
Lyme's arthritis
Gout
Sepsis syndrome
- 15 Hyperthermia
Ulcerative colitis or enterocolitis
Osteoporosis
Cytomegalovirus
Periodontal diseases
- 20 Glomerulonephritis
Chronic, non-infectious inflammation of the lung (e.g. sarcoidosis and smoker's lung)
Granuloma formation
Fibrosis of the liver
- 25 Fibrosis of the lung
Transplant rejection
Graft vs. host disease
Chronic myeloid leukaemia
Acute myeloid leukaemia
- 30 Other neoplastic diseases
Asthma bronchiale
Diabetes mellitus, type I (insulin dependent)
Arteriosclerosis/atherosclerosis
Psoriasis
- 35 Chronic B lymphocyte leukaemia
Common variable immunodeficiency
Side-effects using other biological response modifiers
Disseminated intravascular coagulation

- Systemic sclerosis
 - Encephalomyelitis
 - Lung inflammation
 - Hyper IgE syndrome
 - 5 Enterocolitis
 - Cancer metastasis and growth
 - Adoptive immune therapy
 - Acquired respiratory distress syndrome
 - Sepsis
 - 10 Reperfusion syndrome
 - Postsurgical inflammation
 - Organ transplantation
 - Alopecia
 - AIDS
 - 15 Cutaneous HPV-infection
-

DETAILED DESCRIPTION OF THE INVENTION

Development of an IL-10-homologous nonapeptide with IL-10-like activity:

- 20 Partial sequences of hIL-10 having a length of 9 amino acids was chosen according to the principle that the sequences should possess high homology between vIL-10 and hIL-10, but as low homology to mIL-10 as possible. It was found that a synthetic nonapeptide, IT9302, possessed some immuno-suppressive activities which mimic those of hIL-10 as described in
- 25 further detail in the following examples. IT9302 corresponds to a nonapeptide sequence from the C-terminal end of hIL-10 with the following amino acid sequence:


NH₂-Ala-Tyr-Met-Thr-Met-Lys-Ile-Arg-Asn-COOH (SEQ ID NO:1)

- 30 The nonapeptide IT9302 is very potent to induce different functions and is very stable, and it is presumed that it cannot be incorrectly coupled to receptors. A nonapeptide has been chosen because generally a 9 amino acid polypeptide

sequence is unique for a protein. However, it is to be noted that the 6 amino acids at the very end of hIL-10 seem to be the most important ones. Within the scope of the present invention is thus a substance or polypeptide comprising a sub-
5 sequence of the amino acid sequence Ala-Tyr-Met-Thr-Met-Lys-Ile-Arg-Asn (SEQ ID NO:1).

It is considered likely that some amino acid substitutions will not have adverse effects on the hIL-10 agonist activity as defined herein as long as the threonine, the lysine and
10 the arginine are present and with one amino acid placed inbetween.

The present invention in particular relates to the use of a substance or polypeptide according to the formula:



15 wherein

X_1 is Ala or Gly,

X_2 is Tyr or Phe,

X_3 , X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and


20 X_6 is selected from the group consisting of ^{Asn}Asp, Gln and Glu,

optionally at least one of X_1 , X_2 , X_3 , X_4 , X_5 and X_6 is independently substituted with non-natural or unusual amino acids and/or the peptide is cyclized and/or the peptide is stabilized and/or the amino terminal amino acid residue is acylated and/or the carboxy terminal amino acid residue is amidated, and peptidomimetics modelled on the basis of the above
25 formula for the preparation of a pharmaceutical composition for the reduction of the IL-1-induced TNF α production presumably by the blocking of the IL-1 receptor with IRAP and/or
30 for the prophylaxis or treatment of pancreatitis.


Examples of specific polypeptides which are presumed to be useful for the reduction of TNF α production and/or the prophylaxis or treatment of pancreatitis are as follows:

1. NH₂-Ala-Tyr-Met-Thr-Ile-Lys-Met-Arg-Asn-COOH (SEQ ID NO:2)
- 5 2. NH₂-Ala-Phe-Met-Thr-Leu-Lys-Leu-Arg-Asn-COOH (SEQ ID NO:3)
3. NH₂-Ala-Tyr-Met-Thr-Met-Lys-Val-Arg-Glu-COOH (SEQ ID NO:4)
4. NH₂-Gly-Tyr-Met-Thr-Met-Lys-Ile-Arg-Asp-COOH (SEQ ID NO:5)
5. NH₂-Ala-Phe-Met-Thr-Met-Lys-Ile-Arg-Asp-COOH (SEQ ID NO:6)
6. NH₂-Ala-Tyr-Ile-Thr-Met-Lys-Ile-Arg-Asp-COOH (SEQ ID NO:7)
- 10 7. NH₂-Ala-Tyr-Leu-Thr-Met-Lys-Ile-Arg-Asp-COOH (SEQ ID NO:8)
8. NH₂-Ala-Tyr-Val-Thr-Met-Lys-Ile-Arg-Asp-COOH (SEQ ID NO:9)
9. NH₂-Ala-Tyr-Met-Thr-Ile-Lys-Ile-Arg-Asp-COOH (SEQ ID NO:10)
10. NH₂-Ala-Tyr-Met-Thr-Leu-Lys-Ile-Arg-Asp-COOH (SEQ ID NO:11)
11. NH₂-Ala-Tyr-Met-Thr-Val-Lys-Ile-Arg-Asp-COOH (SEQ ID NO:12)
- 15 12. NH₂-Ala-Tyr-Met-Thr-Met-Lys-Ile-Arg-Asp-COOH (SEQ ID NO:13)
13. NH₂-Ala-Tyr-Met-Thr-Met-Lys-Met-Arg-Asp-COOH (SEQ ID NO:14)
14. NH₂-Ala-Tyr-Met-Thr-Met-Lys-Val-Arg-Asp-COOH (SEQ ID NO:15)
15. NH₂-Ala-Tyr-Met-Thr-Met-Lys-Ile-Arg-Gln-COOH (SEQ ID NO:16)
16. NH₂-Ala-Tyr-Met-Thr-Met-Lys-Ile-Arg-Glu-COOH (SEQ ID NO:17)


- 20 The present invention in particular relates to a polypeptide having the formula




a polypeptide having the formula



- 25 a polypeptide having the formula



and a polypeptide having the formula



wherein

X₁ is Ala or Gly,

X₂ is Tyr or Phe,

X₃, X₄ and X₅ are independently selected from the group consisting of Met, Ile, Leu and Val; and

5 X₆ is selected from the group consisting of ^{Asn,} Asp, Gln and Glu,

wherein one or more amino acids are substituted with non-natural or unusual amino acids and/or the peptide is cyclized and/or the amino terminal amino acid residue is acylated and/or the carboxy terminal amino acid residue is amidated,
10 and peptidomimetics modelled on the basis of the above formula, said analogues having at least one of the following properties:

- a) induces inhibition of spontaneous IL-8 production by human monocytes,
- 15 b) induces inhibition of IL-1 β induced IL-8 production by human peripheral blood mononuclear cells (PBMC),
- c) induces production of interleukin-1 receptor antagonistic protein (IRAP) by human monocytes,
- d) induces chemotactic migration of CD8+ human T lymphocytes *in vitro*,
- 20 e) desensitizes human CD8+ T cells resulting in an unresponsiveness towards rhIL-10,
- f) suppresses the chemotactic response of CD4+ T human lymphocytes towards IL-8,
- 25 g) suppresses the chemotactic response of human monocytes towards MCAF/MCP-1,
- h) inhibits class II MHC molecule expression on human monocytes stimulated by IFN- γ ,
- i) induces the production of IL-4 by cultured normal human
30 CD4+ T cells,
- j) reduces the TNF α production in human mixed leukocyte reaction,
- k) downregulates TNF α and IL-8 production in a rabbit model of bile acid induced acute pancreatitis and reduces neutrophil infiltration in the lungs of the treated rabbits.
35

By use of the term "at least one biological activity of IT9302" in the present specification and claims, reference is meant to be to at least one of the above mentioned properties.

5 Any of the contemplated peptides of the invention can have an amino terminal amino acid residue which is acylated such as acetylated or benzoylated. Also, any of the contemplated peptides can have a carboxy terminal amino acid residue which is amidated.

10 The present invention further contemplates analogues of peptides formed by other conservative amino acid substitutions than the specific substitutions proposed above, substitutions of unusual or non-natural amino acids, stabilization of peptides, cyclization of peptides, and peptidomimetics modelled on the identified IL-10 agonist peptides.

15 The principle behind conservative amino acid substitution is that certain amino acid pairs have compatible side chains such that, when one is substituted for the other, there will be only minimal changes in the tertiary structure and the binding affinity of the peptide. Rules for conservative substitution are explained in (78).

"Conservative" as used herein means (i) that the alterations are as conformationally neutral as possible, that is, designed to produce minimal changes in the tertiary structure of the mutant polypeptides as compared to the native protein, and (ii) that the alterations are as antigenically neutral as possible, that is designed to produce minimal changes in the antigenic determinants of the mutant polypeptides as compared to the native protein. Conformational neutrality is desirable for preserving biological activity, and antigenic neutrality is desirable for avoiding the triggering of immunogenic responses in patients or animals treated with the substances of the invention. Although it is difficult to select with absolute certainty which alternatives will be conformational-

ly and antigenically neutral, rules exist which can guide those skilled in the art to make alterations that have high probabilities of being conformationally and antigenically neutral, see e.g. (77) and (78). Some of the more important rules include (1) replacement of hydrophobic residues is less likely to produce changes in antigenicity because they are likely to be located in the protein's interior, e.g. Berzofsky (cited above) and Bowie et al. (cited above); (2) replacement of physicochemically similar, i.e. synonymous, residues is less likely to produce conformational changes because the replacing amino acid can play the same structural role as the replaced amino acid; and (3) alteration of evolutionarily conserved sequences is likely to produce deleterious conformational effects because evolutionary conservation suggests sequences may be functionally important. In addition to such basic rules for selecting mutein sequences, assays are available to confirm the biological activity and conformation of the engineered molecules. Changes in conformation can be tested by at least two well known assays: the microcomplement fixation method, e.g. (79) and (80) used widely in evolutionary studies of the tertiary structures of proteins; and affinities to sets of conformation-specific monoclonal antibodies, e.g. (81). Biological assays for the substances of the invention are described more fully in the examples:

Inhibition of spontaneous IL-8 production by human monocytes is tested as outlined in Example 1 using the synthesized substance or peptide instead of IT9302. If the IL-8 production is suppressed to be no more than 50% when 1 ng/ml of the substance or peptide is used, then the substance or peptide is within the scope of the present invention.

Inhibition of IL-1 β induced IL-8 production by human peripheral blood mononuclear cells (PBMC) is tested as outlined in Example 2 using the synthesized substance or peptide instead of IT9302. If the percent inhibition of IL-8 production is at least 50% when 1 ng/ml of the substance or peptide is used,

then the substance or peptide is within the scope of the present invention.

Production of interleukin-1 receptor antagonistic protein (IRAP) by human monocytes is tested as outlined in Example 3 using the synthesized substance or peptide instead of IT9302. If the induction of IRAP is at least 30 ng/ml when 10 ng/ml of the substance or peptide is used, then the substance or peptide is within the scope of the present invention.

Induction of chemotactic migration of CD8+ human T lymphocytes *in vitro* is tested as outlined in Example 4 using the synthesized substance or peptide instead of IT9302. If the potency of the substance or peptide when a concentration of 10 ng/ml is used is present, i.e. 2 or more, then the substance or peptide is within the scope of the present invention.

Desensitization of human CD8+ T cells resulting in an unresponsiveness towards rhIL-10 is tested as outlined in Example 5 using the synthesized substance or peptide instead of IT9302. If preincubation of cells with the substance or peptide results in a substantially totally suppressed responsiveness of the CD8+ cells towards hrIL-10, i.e. giving a value of about 1, such as 0.8 to 1.2, at a concentration of the substance or peptide of 10 ng/ml, then the substance or peptide is within the scope of the present invention.

Suppression of the chemotactic response of CD4+ human T lymphocytes towards IL-8 is tested as outlined in Example 6 using the synthesized substance or peptide instead of IT9302. If addition of the substance or peptide to a suspension of human CD4+ T lymphocytes results in a substantially total inhibition of the response of the CD4+ cells towards IL-8, i.e. giving a value of about 1, such as 0.8 to 1.2, at a concentration of the substance or peptide of 10 ng/ml, then the substance or peptide is within the scope of the present invention.

Suppression of the chemotactic response of human monocytes towards MCAF/MCP-1 is tested as outlined in Example 7 using the synthesized substance or peptide instead of IT9302. If addition of the substance or peptide to a suspension of human
5 monocytes results in a substantially total inhibition of the chemotactic response of the monocytes towards MCAF/MCP-1, i.e. giving a value of about 1, such as 0.8 to 1.2, at a concentration of the substance or peptide of 10 ng/ml, then the substance or peptide is within the scope of the present
10 invention.

Inhibition of class II MHC molecule expression on human monocytes stimulated with IFN- γ is tested as outlined in Example 8 using the synthesized substance or peptide instead of IT9302. IFN- γ upregulated MHC II antigen expression in the
15 cell population from 36.8% to 58.4%, and this stimulation was blocked or downregulated to 25.2% by 10 ng/ml rhIL-10 and to 31.2% by 1 ng/ml IT9302 (Fig. 12). If a substance or peptide blocks or downregulates class II MHC expression on monocytes to the unstimulated level, when added in an amount of 1-10
20 ng/ml, then the substance or peptide is within the scope of the present invention.

If addition of the substance or peptide is capable of blocking the effect of the IFN γ stimulation at a concentration of the substance or peptide of 10 ng/ml, then the substance or
25 peptide is within the scope of the present invention.

Induction of the production of IL-4 by cultured normal human CD4+ T cells is tested as outlined in Example 9 using the synthesized substance or peptide instead of IT9302. If addition of the substance or peptide induces the production of
30 IL-4 in CD4+ T lymphocytes at a concentration of the substance or peptide of 10 ng/ml, then the substance or peptide is within the scope of the present invention.

Reduction of the TNF α production in human mixed leukocyte reaction is tested as outlined in Example 10 using the syn-

thesized substance or peptide instead of IT9302. If addition of the substance or peptide significantly reduces the production of $\text{TNF}\alpha$ in human mixed leukocyte reaction within 24 hours at a concentration of the substance or peptide of 10 ng/ml, then the substance or peptide is within the scope of the present invention.

Downregulation of $\text{TNF}\alpha$ and IL-8 production in a rabbit model of bile acid induced acute pancreatitis and reduction of neutrophil infiltration in the lungs of the treated rabbits is tested as outlined in Example 14 using the synthesized substance or peptide instead of IT9302. If addition of the substance or peptide significantly reduces the mortality of the test animals, when the substance or peptide is added at a concentration of 100 $\mu\text{g/kg}$, then the substance or peptide is within the scope of the present invention.

An important embodiment of the present invention thus relates to a polypeptide in which at least one amino acid residue has been substituted with a different amino acid residue and/or in which at least one amino acid residue has been deleted or added so as to result in a polypeptide comprising an amino acid sequence being different from the amino acid sequence or a subsequence of said amino acid sequence as defined in the following, but essentially having hIL-10 agonist activity as defined above.

Analogues of synthetic peptides can also be made by substituting individual residues with non-natural or unusual amino acids. Sequences of bioactive peptides are originally derived from proteins which are made up of the naturally occurring twenty L-amino acid residues. However, the process of chemical synthesis used to construct synthetic peptides allows for the substitution of alternate residues including D-amino acids, β -amino acids, N-substituted amino acids, infrequently occurring natural amino acids, or non-natural synthetic amino acid analogues (93). Non-limiting examples of amino acids useful in the present invention are:

	Aad	2-Aminoadipic acid
	bAad	3-Aminoadipic acid
	bAla	beta-Alanine, beta-Aminopropionic acid
	Abu	2-Aminobutyric acid
5	4Abu	4-Aminobutyric acid, piperidinic acid.
	Acp	6-Aminocaproic acid
	Ahe	2-Aminoheptanoic acid
	Aib	2-Aminoisobutyric acid
	bAib	3-Aminoisobutyric acid
10	Apm	2-Aminopimelic acid
	Dbu	2,4-Diaminobutyric acid
	Des	Desmosine
	Dpm	2,2'-Diaminopimelic acid
	Dpr	2,3-Diaminopropionic acid
15	EtGly	N-Ethylglycine
	EtAsn	N-Ethylasparagine
	Hyl	Hydroxylysine
	aHyl	allo-Hydroxylysine
	3Hyp	3-Hydroxyproline
20	4Hyp	4-Hydroxyproline
	Ide	Isodesmosine
	aIle	allo-Isoleucine
	MeGly	N-Methylglycine, sarcosine
	MeIle	N-Methylisoleucine
25	MeLys	6-N-Methyllysine
	MeVal	N-Methylvaline
	Nva	Norvaline
	Nle	Norleucine
	Orn	Ornithine

30 Further and non-limiting examples of infrequently occurring, non-natural amino acids or building blocks are listed as follows: Novabiochem 1994/95 Catalog (Calbiochem-Novabiochem AG, Weidenmattweg 4, CH-4448 Läufelfingen/Switzerland), pp. 65-125; Bachem Feinkemikalien AG 1995 Catalog (Bachem Feinkemikalien AG, Hauptstrasse 144, CH-4416 Bubendorf/Switzerland), pp. 753-831; Neosystem Laboratoire Catalogue 1997/98

(Neosystem Laboratoire, 7 rue de Boulogne, 67100 Strasbourg, France), pp. 131-176.

The above described alternate residues can be used (a) to replace chemically reactive residues and improve the stability of the synthetic peptide towards e.g. enzymatic and proteolytic degradation, (b) to provide analytic labels useful in the detection of the synthetic peptide, and (c) to modulate the bioactivity of the synthetic peptide by increasing or decreasing the binding affinity of the peptide for the IL-10 receptor, e.g. by introduction of conformational constraints which reduce the rotational freedom for specific chemical bonds.

Within the scope of the present invention are further substances wherein one or more of the residues Thr, Lys or Arg in the above formula is substituted with non-natural or unusual amino acids as proposed above. All polypeptide sequences in the present specification and claims are, also when not explicitly stated, written from the N-terminal to the C-terminal end in the conventional format.

The method of choice for synthesis of the peptides and their analogues is solid-phase peptide synthesis (SPPS). This method was introduced by Merrifield (100) in 1963, and numerous peptides have been synthesized since then with this technique. An excellent review of the current chemical synthesis of peptides and proteins is given by S.B.H. Kent (101).

In practice, peptides are assembled by stepwise SPPS. The C-terminal amino acid in the form of an N- α -protected, if necessary side chain-protected reactive derivative, is covalently coupled either directly or by means of a suitable linker to a solid support, e.g. a polymeric resin, which is swollen in an organic solvent. The N- α -protective group is then removed and the succeeding protected amino acids according to the desired sequence are added in a stepwise manner.

After assembly of the complete peptide chain, the side chain-protective groups are removed, and the peptide is cleaved from the resin, which may be done simultaneously or in separate steps.

- 5 Among the several different coupling strategies which have emerged over the years, two are currently in general use, based on the different N-alfa-protective groups and matching side chain-protective groups. Merrifield used tert.butyloxy-carbonyl (Boc) as the N-alfa-protective group, while 9-fluor-
10 enylmethoxycarbonyl (Fmoc) was introduced by Carpino and Han (102). The practical application of these two strategies including the choice of solid supports, side chain-protecting groups, activation procedures, cleavage procedures, instrumentation, and analytical and monitoring techniques have been
15 given in several monographs among which should be mentioned the following: Stewart and Young (103), Atherton and Sheppard (104), and Pennington and Dunn (105). Peptides and their analogues with unusual or non-natural amino acids in the present invention are conveniently synthesized according to
20 these protocols.

Analogues of synthetic linear peptides can be made by chemically converting the structures to cyclic forms. Cyclization of linear peptides can modulate bioactivity by increasing or decreasing the affinity of binding of the peptide by the
25 target protein (94). Linear peptides are very flexible and tend to adopt many different conformations in solution. Cyclization acts to constrain the number of available conformations and thus favour the more active or inactive structures of the peptide. The immunogenicity of synthetic peptides
30 has been correlated with the experimentally observed conformational preferences in solution (95). Differences in immunogenicity may be indicative of differences in binding affinity of specific antibodies for cyclic peptides.


Cyclization of linear peptides is accomplished either by
35 forming a peptide bond between the free N-terminal and C-

terminal ends (homodetic cyclopeptides) or by forming a new covalent bond between amino acid backbone and/or side chain groups (heterodetic cyclopeptides) (93). The latter cyclizations use alternate chemical strategies to form covalent bonds, e.g. disulfides, lactones (both also present in natural peptides), ethers, or thioethers. Linear peptides of more than five residues can be cyclized relatively easily. The propensity of the peptide to form a beta-turn conformation in the central four residues facilitates the formation of both homo- and heterodetic cyclopeptides. The presence of proline or glycine residues at the N- or C-terminal ends also facilitates the formation of cyclopeptides, especially from linear peptides shorter than six residues in length.

Examples of protocols for the formation of disulfide bonds and for other cyclization reactions of peptides are given in Pennington and Dunn (105), chapters 7 and 11.

Peptidomimetics technology is the design of molecular mimics of peptides. The ability to successfully design such molecules depends on the understanding of the properties of the linear peptide sequence and the conformation in which it is presented to the IL-10 receptor. The synthesis of mimetics can provide compounds exhibiting greater biological activity, improved solubility, and stability (96).

As an example, the following peptidomimetic has been derived on the basis of the α -helical templates in C-terminal peptide mimetics of cytokines disclosed in US 5,446,128 (97) in combination with the knowledge that the C-terminal of IL-10 exists as an α -helix (98).



By this attachment of a small molecule at the N-terminal of the peptide, an α -helical structure of the synthetic peptide is stabilized, and the peptide is made more resistant to proteolytic degradation. Other peptidomimetics may be derived on the basis of the disclosure in US 5,446,128. Such substances wherein substitution has taken place at other residues than X_1 and/or substitution has taken place with other molecules than the N-terminal molecule shown in the formula above are within the scope of the present invention.

In accordance with the present invention, the term "an analogue of the peptide" comprises any pharmaceutically active and acceptable compound derived on the basis of the above formulae and exhibiting at least one biological activity similar to IT9302, including derivatives of such analogues, especially pharmaceutically acceptable salts, esters and solvates thereof.

The following terms: "cytokine", "lymphokine", "interleukin", "monokine", "chemokine", "interferon", "colony-stimulating factor", and "polypeptide" are used as defined in WO 96/01318.

An interesting embodiment of the invention relates to a polypeptide of the invention where the number of amino acids amount in total from 6, 7, 8, 9 or 10 up to about 100 amino acids, e.g. 11, 12, 13, 14 or 15 amino acids, or even larger such as 20 amino acids or 30 amino acids.

In a preferred embodiment of the invention, the substance or polypeptide is used in substantially pure form. To obtain this, purification of the polypeptide may be required. Examples of the procedures employed for the purification of polypeptides are: (i) immunoprecipitation or affinity chromatography with antibodies, (ii) affinity chromatography with a suitable ligand, (iii) other chromatography procedures such as gel filtration, ion exchange or high performance liquid chromatography or derivatives of any of the above, (iv) elec-

trophoretic procedures like polyacrylamide gel electrophoresis, denaturing polyacrylamide gel electrophoresis, agarose gel electrophoresis and isoelectric focusing, (v) any other specific solubilization and/or purification techniques.

- 5 Within the scope of the present invention is also a pharmaceutical composition comprising a substance or polypeptide of the invention and a pharmaceutically acceptable excipient. The composition may comprise e.g. purified synthesized protein or a purified recombinant polypeptide.

- 10 The IL-10 agonist used in this invention may be prepared as formulations in pharmaceutically acceptable media, for example, saline, phosphate buffered saline (PBS), Ringer's solution, dextrose/saline, Hank's solution, and glucose. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as buffering agents, tonicity adjusting agents, wetting agents, detergents, and the like. Additives may also include additional active ingredients, e.g. bactericidal agents, or stabilizers. The amount administered to the
15 patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the host, the manner of administration, and the like.

- 25 The pharmaceutical compositions are typically intended for transcutaneous or parenteral administration, e.g. intravenously, subcutaneously, or intramuscularly. Orally administrable forms are also desired and can be provided by modifying the composition to bypass the stomach environment. The composition can be used for prophylactic and/or therapeutic
30 treatment.

Pharmaceutical compositions of the invention suitable for topical administration may e.g. be creams, ointments, lotions, liniments, gels, solutions, suspensions, pastes, sticks, sprays, or powders. The composition may be impreg-

nated or distributed onto e.g. pads, plasters or strips and is conveniently applied 1-10 times a day.

The topical compositions will generally comprise 1-80% of the active compound by weight, based on the total weight of the preparations, such as 0.001-25% w/w of the active compound, e.g., 0.1-10%, 0.5-5%, or 2-5%. The composition may be formulated in accordance with conventional pharmaceutical practice with pharmaceutical excipients conventionally used for topical applications. Vehicles other than water that can be used in compositions can include solids or liquids such as emollients, solvents, humectants, thickeners and powders.

The pH of the composition may in principle be within a very broad range such as 3-9, although a pH of about 4 to 8 is preferred. Conventional buffering agents may be used to obtain the desired pH.

As an example, a composition for transcutaneous administration can contain 1 mg of substance (IT9302) dissolved in 1 g of cream basis such as Moistion's neutral cream with 0.05% salicylic acid (the pharmacy of Århus Kommunehospital) and be applied in amount of 0.4-0.5 mg under plastic on the skin. This composition is used in Examples 16 and 17.

Pharmaceutical compositions may alternatively be administered intravenously. Thus, the invention provides compositions which comprise an IL-10 agonist substance dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The IL-10 agonist may also be administered with a second biologically active agent, such as a standard chemotherapeutic agent. Such agents include but are not limited to vincristine, daunorubicin, L-asparaginase, mitoxantrone and amsacrine.

In therapeutic applications, the pharmaceutical compositions are administered to a patient in an amount sufficient to produce the desired effect, defined as a "therapeutically effective dose". The therapeutically effective dose of an IL-10 agonist will vary according to, for example, the particular use for which the treatment is made, the manner of administration, the health and condition of the patient, and the judgment of the prescribing physician. For example, the dose for continuous infusion will typically be between 500 ng/kg/day and 50 μ g/kg/day. This dose is calculated on the basis of a randomized controlled trial of IL-10 in humans (90).

The concentration of IL-10 agonist in the pharmaceutical formulations can vary widely, i.e. from about 10 μ g to about 5 mg/ml, preferably between about 100 μ g and about 2 mg/ml. The concentration will usually be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected. Thus, a typical pharmaceutical composition for intravenous infusion could be made up to contain 250 ml of dextrose/saline solution and 2.5 μ g of IL-10 agonist.

For solid compositions, conventional non-toxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable non-toxic composition is formed by incorporating normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, an IL-10 agonist substance, preferably 25-75%.

For aerosol administration, the IL-10 agonist is preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of IL-10 agonist are 0.01-20% by weight, preferably 1-10%. The surfactant must, of course, be non-toxic, and preferably soluble in the propellant. Re-

presentative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride such as, for example, ethylene glycol, glycerol, erythritol, arbutol, mannitol, sorbitol, the hexitol anhydrides derived from sorbitol, and the polyoxyethylene and polyoxypropylene derivatives of these esters. Mixed esters, such as mixed or natural glycerides may be employed.

The surfactant may constitute 0.1-20% by weight of the composition, preferably 0.25-5%. The balance of the composition is ordinarily propellant. Liquified propellants are typically gases at ambient conditions, and are condensed under pressure. Among suitable liquified propellants are the lower alkanes containing up to 5 carbons, such as butane and propane; and preferably fluorinated or fluorochlorinated alkanes. Mixtures of the above may also be employed. In producing the aerosol, a container equipped with a suitable valve is filled with the appropriate propellant, containing the finely divided polypeptide(s) and surfactant. The ingredients are thus maintained at an elevated pressure until released by action of the valve.

To enhance the serum half-life, the IL-10 agonist may be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques may be employed which provide an extended lifetime of the polypeptides. Thus, in certain embodiments, the IL-10 agonist may be encapsulated in a liposome. A variety of methods are available for preparing liposomes, as described in, e.g., (83), (84), (85) and (86).

As described above it has been found that IT9302 and analogues and variants thereof are useful for preventing effects of cytokines known to be pathogenetically involved in the previously described pathological conditions.

Therefore, the potentials of therapy by using the polypeptide of the invention or analogues or derivatives thereof is contemplated and should be investigated in all diseases where a therapeutic effect of hIL-10 and/or IRAP is expected (see
5 above, Tables 1 and 2).

LEGENDS TO FIGURES

Fig. 1 is a diagram showing that IT9302 inhibits spontaneous IL-8 production by purified cultured human monocytes.

Fig. 2 is a diagram showing that IT9302 inhibits IL-1 induced
10 (1 ng/ml) IL-8 production by human peripheral blood mononuclear cells.

Fig. 3 illustrates IRAP production by IT9302-stimulated human monocytes.

Fig. 4 illustrates IRAP production by IL-10-stimulated human
15 monocytes.

Fig. 5 illustrates the chemotactic activity of IT9302 on CD8+ T cells

Fig. 6 illustrates the desensitization of CD8+ T cells by IT9302, resulting in unresponsiveness of CD8+ T cells towards
20 IL-10 (10 ng/ml) induced chemotaxis.

Fig. 7 illustrates the suppression of IL-8 activity on CD4+ T cells by IT9302.

Fig. 8 is a diagram showing that IT9302 inhibits MCAF/MCP-1 induced monocyte chemotaxis.

25 Fig. 9 shows IL-4 production in CD4+ T cell cytosolic fractions by ECL - Western Blotting.

Fig. 10 shows TNF- α production in human mixed lymphocyte culture cytosolic fractions by ECL - Western Blotting. TNF- α Western Blotting was carried out as the IL-4 described in Materials and Methods, but using a rabbit anti-human TNF- α antibody (Pepro Tech. Inc., London, England) and a horse-radish peroxidase-labelled secondary antibody (Cat.no. P 217, Dako, Denmark).

Fig. 11 shows regulation of T cell proliferation by IL-10 and IT9302.

10 Fig. 12 shows HLA-DR expression on human monocytes (flow cytometry).

Fig. 13 shows that LPS induced shock and leukopenia are modulated by IT9302, shown by total leukocyte counting.

15 Fig. 14 shows that injection of murine IT9302 into rabbits before induced pancreatitis prevented leukopenia.

EXAMPLES

Materials and Methods

Cytokines and chemoattractants

Recombinant hIL-10 was obtained from Pepro Tech Inc., NJ.

5 (Cat.No. 200 10). Recombinant hIL-1 β and recombinant hIL-8 were a kind gift from Dainippon Pharmaceutical Company, Osaka, Japan. The culture medium was RPMI 1640 GIBCO, LPS-free according to the Limulus Amoebocyte Lysate assay (Sigma E-TOXATE Kit Cat.No. 210-A1). rhMCAF/MCP-1 was a kind gift
10 from professor Kouji Matsushima, Kanazawa, Japan.

*Leukocyte chemotaxis assay**T cell chemotaxis*

CD4+ and CD8+ T lymphocyte subsets characterized by expressing either CD4 or CD8 antigens were purified from heparinized blood of normal donors. Thus, peripheral blood mononuclear cells (PBMC) were purified from the heparinized blood by diluting 100 ml of the blood with Hanks balanced salt solution (HBSS) 1:1 and then separated by layering the cells on Lymphopac™ (Nycomed Pharma, Oslo, Norway) followed by gradient centrifugation at 2000 rpm for 20 minutes. The mononuclear cells were washed 3 times in HBSS and the cell pellet was diluted in 4 ml of HBSS containing 1% fetal calf serum and sorted at 4°C by using Dynabeads coated with monoclonal antibody towards CD4 or CD8 antigen (Dynabeads M-450 CD4
15 Cat.No. 111.16, Dynabeads M-450 CD8 Cat.No. 111.08, DETACHaBEAD Cat.No. 125.04). The bead:cell ratio was 10:1 and the incubation time 1 hour. The beads were detached by adding polyclonal anti-mouse antibody according to the manufacturer's instructions.

30 The chemotaxis assay was a 48-well microchamber technique (Neuroprobe, Rockville, MD) as previously described (74; see

ref. 3 and ref. 14). Chemoattractants were diluted in RPMI 1640 (GIBCO Cat.No. 61870-010) with 1% sterile filtered fetal calf serum and placed in the lower 25 μ l chamber. In the case of determining T cell chemotaxis, T cells (5×10^6 /ml) were
5 suspended in medium and 50 μ l was placed in the upper chamber separated from the lower chamber by a 5 μ m pore-size polycarbonate, polyvinylpyrrolidone-free filter (Nucleopore Corp., Pleasanton, CA) coated with type IV collagen (Sigma Cat.No. C 0543). Cells were allowed to migrate for 2 hours at
10 37°C at 5% CO₂. The filters were then carefully removed, fixed in 70% methanol, and stained for 5 minutes in Coomassie's Brilliant Blue. Cells attached to the lower surface of the filter were counted by measuring their area using a video camera on the microscope connected to a computer system for
15 digital analysis and supported by software for objective determination of chemotactic migration. Approximately 5% of the T cells will migrate spontaneously corresponding to between 12,000 and 13,000 cells; this may vary from day to day, but very little in the same day's experiments. As has
20 been described earlier (ref. 3 and ref. 14), it was therefore chosen to report the results as a ratio between number of cells migrating in the sample and in the negative control, which reflects spontaneous migration. This ratio is referred to as the chemotactic index (CI). All samples were analyzed
25 in triplicates and cell migration in each well was measured in three fields before the median value of area was estimated. In some experiments the chemotaxis membrane was not coated with collagen, and in the present assay system migrating cells will therefore drop to the bottom of the lower
30 well of the chemotaxis chamber.

In one experiment, the chemotactic activity of IT9302 on CD8+ T cells was performed by testing serial dilutions of IT9302 added to the lower chamber and evaluating chemotaxis as described above.

35 In a second experiment, the ability of IT9302 to desensitize the migration of CD8+ T cells as a response to rHIL-10

(10 ng/ml) was studied by adding IT9302 to the target cells 30 minutes before chemotaxis. IT9302 was added in serial concentrations and the chemotactic response of rhIL-10 was evaluated as described above.

- 5 In a third experiment, the ability of IT9302 to suppress the chemotactic response of CD4+ T cells towards rhIL-8 (10 ng/ml) was studied by adding IT9302 to the target cells 30 minutes before performing chemotaxis. IT9302 was added in serial concentrations and the chemotactic response of rhIL-8
10 was evaluated as described above.

Monocyte chemotaxis

- Monocyte chemotaxis was measured using the same Boyden chamber equipment as described for T cells above. The chemo-attractant MCAF/MCP-1 was diluted in RPMI 1640 medium with
15 0.5% BSA and added to the lower chamber at a concentration of 10 ng/ml. Monocytes, purified by the standard plastic adherence technique, from normal human PBMC, obtained as described above were suspended in RPMI 1640 medium with 0.5% BSA and then incubated for 30 minutes in the presence of IT9302
20 at different concentrations. Subsequently, the cells were added to the upper chemotaxis chambers at a concentration of 10^6 cells/ml. The upper and lower chambers were separated by an 8 μ m pore size polyvinyl pyrrolidone-free polycarbonate filter (Nucleopore, Pleasanton, CA). The chamber was incubated
25 at 37°C for 90 minutes. The membranes containing migrating cells were treated as described above and a chemotactic index calculated according to the technique described above.

Production of IL-8 by normal human peripheral mononuclear cells (PBMC)

- 30 PBMC was purified from heparinized blood of normal human donors. Following gradient centrifugation with Lymphoprep™ (Nycomed Pharma, Oslo, Norway), the mononuclear cells were diluted to 2×10^6 cells/ml in LPS-free RPMI 1640 medium

(Gibco Cat.No. 6187-010) containing 1% sterile filtered heat-inactivated fetal calf serum and penicillin (10,000 IE/ml), streptomycin (10 mg/ml) and gentamycin (2.5 mg/ml). Cells were cultured in 24 wells Nunc Micro Plates (Nunc, Denmark) and in the presence of different concentration of IT9302 (0, 1 µg, 100 ng, 10 ng, 1 ng, 0.1 ng, 0.01 ng/ml) for 24 hours. Following 24 hours of incubation, another dose of IT9302 was added once more, and 1 hour later r-hIL-1β (1 ng/ml) was added to the cell cultures. Supernatants were collected after a total of 48 hours of incubation, and the concentration of the secreted IL-8 was measured by IL-8 ELISA by using an IL-8 ELISA Kit (Dainippon Pharmaceutical Co. Ltd, Osaka, Japan). Briefly, standards and cell supernatants were incubated for one hour and in duplicates at 20°C on a micro-plate shaker. Then after washing, a second antibody was added for one hour, followed by one hour of incubation with peroxidase-labelled goat anti-rabbit IgG. After washing, the reaction was developed with O-phenylenediamine. Thirty minutes later the reaction was stopped with 1.6 N sulphuric acid. Optical density (OD) was measured in an ELISA reader at 490 nm. IL-8 concentration was calculated by a calibration curve of absorbance of unknown vs concentrations of IL-8 standards.

Determination of IRAP concentration

PBMC was purified as described above. PBMC was cultured in RMPI 1640, 10% sterile heat-inactivated fetal calf serum (including penicillin 10,000 IE/ml, streptomycin 10 mg/ml, gentamycin 2.5 mg/ml) and the cell concentration was 5×10^6 cells/ml. The monocytes were then purified by standard plastic adherence technique. Monocytes were then cultured in RPMI 1640 with 2% FCS (2.5×10^6 cells/ml) and with different dilutions of rhIL-10 or IT9302. The cells were stimulated for 24 hours and the supernatants were collected for IRAP determination. IRAP ELISA was carried out by using Human IL-1ra Quantikin Immunoassay Kit from R&D Systems Europe Ltd. (Cat.No. DRA 00, Abingdon, Oxon, UK).

Determination of T cell proliferation

Proliferation assay. PBMCs (2×10^5) were cultivated in 200 μ l of RPMI medium with 10% FCS for 72 hours with PHA 0.5 μ l/ml and rhIL-10 (1, 10, 100 ng/ml) or IT9302 (0.1, 1, 10 ng/ml) in triplets. The last 18 hours 3 H-thymidine was added with 0.5 μ Ci/well (Amersham, Denmark). The cells were harvested on a filter (Glass Microfibre Filters, Whatman, Cat.No. 1822 849) and scintillation fluid (Ultima, Gold MV, Packard) was added. The scintillation counting was made on Tri-Carb model 1600 TR, Packard.

Determination of class II MHC antigen expression on monocytes

HLA-DR expression on human monocytes. The monocytes were isolated from fresh, heparinized blood by adherence to plastic at 37°C in RPMI 1640 containing 10% FCS. After incubation, the supernatant was removed, Hank's solution (4°C with 1% FCS) was added, and the cells were detached by cooling at -20°C for 15 minutes and gentle banging to the table. Monocytes were stimulated (2×10^6 cells/ml) in RPMI 1640 added 2% FCS, with IFN- γ (10 ng/ml), or rhIL-10 (100, 10, 1 ng/ml) added before IFN- γ , or IT9302 (10, 1, 0.1 ng/ml) added before IFN- γ for 40 hours. The cells were detached from the wells by cooling as before. Fresh, non-fixed cells were used for surface typing by antihuman antibody for HLA-DR. The cells were resuspended in Hank's solution with 1% FCS, 1×10^6 cells/ml and FITC conjugated mouse-anti-human HLA DR, DP, DK antibodies were added (F 0817, DAKO Denmark) for 45 minutes. The cells were washed three times in Hank's solution and a FACS analysis was performed on a Coulter-Epics XL-MCL flow cytometer at a wavelength of 488 nm. Non-specific binding was determined with a non-relevant Fitch conjugated antibody (mouse anti goat DAKO F 479).

Alternatively cells were fixed in 10% DMSO, 40% RPMI 1640 and 50% sterile FCS, and stored at -80°C and used for DNA typing.

Determination of apoptosis in monocytes

DNA typing of the stimulated monocytes. The fixed cells were incubated in 70% ethanol for 60 minutes and washed twice in Hank's solution. 1×10^6 cells were resuspended in 250 μ l of
5 RNase 1 μ g/ml in 1.12% sodium citrate, pH 8.4 (Ribonuclease A, Pharmacia No. 17-0442-01) and incubated at 37°C for 3 minutes. Thereafter, 250 μ l of propidiumiodide (50 μ g/ml in Hank's solution) was added, and cells were incubated in the dark for 30 minutes. After this the cells were washed twice
10 in Hank's solution (Jensen et al., (110)). The DNA content was measured by flow cytometry on a Coulter-Epics XL-MCL at a wavelength of 550 nm.

Results

Regulation of T cell proliferation by IL-10 and IT9302

15 PBMC's were stimulated with PHA as described above and rhIL-10 and IT9302 were added for 72 hours, and the 3 H-thymidine incorporation was measured for the last 18 hours. Both rhIL-10 and IT9302 downregulated cell proliferation in an optimum concentration of 100 ng/ml rhIL-10 and 10 ng/ml
20 IT9302, as seen in Fig. 11.

HLA-DR expression on human monocytes

The monocytes were purified as described above and stimulated for 40 hours by IFN- γ (10 ng/ml) and/or rhIL-10 and/or IT9302 added 30 minutes before IFN- γ . MHC II antigen expression was
25 studied by incubation with FITC conjugated mouse-anti-human HLA DR, DP, DK antibody. The expression of MHC II antigen was upregulated by IFN- γ as seen in Fig. 12, and 10 ng/ml rhIL-10 and 1 ng/ml IT9302 downregulated the MHC II antigen expression in a similar way.

DNA typing of the stimulated monocytes

The IFN- γ stimulated monocytes from above were incubated with propidium iodide and the DNA content was measured by flow cytometry. The fraction of cells expressing DNA in G₁ or G₂ phase of cell proliferation was measured and also the fraction expressing apoptosis. As seen in Fig. 12, non-stimulated monocytes were expressing 6.6% apoptosis, IFN- γ stimulation downregulated apoptosis to 4.1%, while both IL-10, IFN- γ and IT9302 + IFN- γ stimulation of the cells induce the apoptotic fraction to 10.3% and 9.3%, respectively.

Determination of IL-4 production by CD4+ T lymphocytes

Cell cultures

CD4+ T lymphocytes were purified from heparinized normal human blood. Following Lymphoprep™ (Nycomed Pharma, Oslo, Norway) gradient centrifugation, the mononuclear cells were further sorted at 4°C using Dynabeads (Dynal AS, Norway) coated with monoclonal anti-CD4 antibodies. The beads were detached by adding polyclonal anti-mouse antibody (Dynal AS, Norway). The purity of the positively selected cells were higher than 99% as judged by FACS analysis. When examining the *de novo* production of IL-4 by IL-8-stimulated T cells, T cells were cultures, 5×10^6 cells/ml in LPS-free RPMI 1640 (Gibco Cat.no. 61870-010) containing 1% sterile-filtered, heat-inactivated fetal calf serum (FCS), penicillin (10,000 IU/ml), streptomycin (10 mg/ml) and gentamycin (2.5 mg/ml).

T cells were stimulated for 3 days using rIL-8 (100 ng/ml), rIL-10 (100 ng/ml), IT9302 (10 ng/ml) and IFN- γ (10 ng/ml). Recombinant human IL-8 (rh IL-8) was a kind gift from Dainippon Pharmaceuticals Co. Ltd., Osaka, Japan), and IFN- γ was purchased from Boehringer Ingelheim Am Rhein, Germany. To obtain specific inhibition of IL-8 stimulation, a neutralizing monoclonal anti-IL-8 antibody (WS.4) was used (a kind

gift from Dr. K. Matsushima, Japan). Recombinant IL-10 was purchased from Pepro Tech. Inc. (London, England).

Preparation of cell material and culture supernatant for gel electrophoresis

- 5 Cultured T cells and culture media were separated by centrifugation at 2000 rpm for 5 minutes. The supernatants were freeze-dried and then dissolved in 100 μ l of lysis buffer. The cells were resuspended directly in 100 μ l of gel lysis buffer (9). The material was kept at -80°C until further
10 examination.

ECL-Western blotting of CD4+ T cell derived proteins

- Cells or freeze-dried cell culture supernatants were used for IL-4 protein content determination. Proteins from one-dimensional 15% SDS-PAGE gels were transferred by blotting onto
15 Hybond-ECL nitrocellulose membranes (Amersham RPN 2020D, UK) and blocked with 5% bovine serum albumin (Sigma) in Tris buffer saline pH 7.8 containing 0.1% Tween-20. The blots were then incubated with a polyclonal goat anti-human IL-4 antibody (R&D Systems, UK) followed by a horseradish peroxidase-
20 labelled secondary antibody (Cat.no. RPN 2106 ECL, Amersham, UK), and the immunostaining was detected by exposing a film (Kodak X-OMAT-S, USA) for 90 seconds.

EXAMPLE 1

Inhibition of spontaneous IL-8 production by human monocytes

- 25 The test was performed as described in "Production of IL-8 by normal human peripheral mononuclear cells (PBMC)". Monocytes were purified by plastic adherence technique and 3.0×10^6 cells/ml were stimulated for 40 hours. As shown in Fig. 1, IT9302 inhibited the production of IL-8 by monocytes, and at
30 0.1 ng/ml of IT9302 the IL-8 production was suppressed to 35% of the spontaneous production *in vitro*. The viability of

cells always exceeded 80% after 1 day in culture and the addition of IT9302 did not in this or in the following examples affect viability at any concentration of IT9302 between 0.1 and 1000 ng/ml (IT9302 MW: 1,127 dalton, rhIL-10 predicted MW: 18,400 dalton).

EXAMPLE 2

Inhibition of IL-1 β induced IL-8 production by human peripheral blood mononuclear cells (PBMC)

The test was performed as described in "Production of IL-8 by normal human peripheral blood mononuclear cells (PBMC)". As shown in Fig. 2, IT9302, in a dose dependent manner, inhibited the IL-1 β induced production of IL-8 by human peripheral blood mononuclear cells *in vitro*. The suppression of IL-8 production plateaued at IT9302 concentrations between 0.01 and 100 ng/ml.

EXAMPLE 3

Production of interleukin-1 receptor antagonist protein (IRAP) by human monocytes

The test was performed as described in "Determination of IRAP concentration". As shown in Fig. 3, IT9302 dose-dependently induced the production of IRAP by human monocytes. The production drastically increased when using concentrations of IT9302 above 10 ng/ml. Fig. 4 shows the induction of IRAP by rhIL-10 and since hIL-10 is approximately 20 times larger than IT9302, 5 ng/ml of IT9302 equals 100 ng/ml of IL-10 in molarity. Therefore the potencies of IT9302 and rhIL-10 are comparable and approximately equal with respect to the induction of IRAP at lower concentrations. At IT9302 concentrations exceeding 10 ng/ml, the induction of IRAP increased and reached a maximum level of 60 ng/ml. Further, the specificity of this induction by the antibody which is specifically directed against IT9302 was tested. In a separate experiment

where the monocytes spontaneously produced 3.5 ng/ml IRAP and they were induced by 1-10 ng/ml IT9302 to a maximum IRAP production of 10.6 ± 0.6 ng/ml, this production could be blocked by a polyclonal antibody for IT9302, 2 μ g/ml added 30 minutes before 10 ng/mg IT9302, so the level of IRAP was downregulated to 2.9 ± 0.3 ng/ml. This results is in contrast to the result obtained with the antibody directed against IL-10, 19F1, which added in the same way (2 μ g/ml 30 minutes before 10 ng/ml IT9302) did not block IRAP production but on the contrary upregulated this to 22 ng/ml. This result can be explained by that this antibody is able to neutralize endogenous IL-10 but not IT9302. The spontaneously produced IL-10 in the cell culture has a negative autoregulatory effect on IRAP production by IT9302.

15 EXAMPLE 4

The chemotactic effect on human CD8+ T lymphocytes

The experiment was carried out as described in "Leukocyte chemotaxis assay". As shown in Fig. 5, IT9302 induced the chemotactic migration of CD8+ human T lymphocytes *in vitro*, while there was no effect on CD4+ T cells (data not shown). Again, the potency of IT9302 shown in this experiment is comparable with that of rhIL-10 shown previously (14).

EXAMPLE 5

Desensitization of human CD8+ T cells resulting in an unresponsiveness towards rhIL-10

The experiment was carried out as described in "Leukocyte chemotaxis assay". IT9302 was added to a suspension of CD8+ T cells 30 minutes before these cells were tested towards their chemotactic response to rhIL-10. As shown in Fig. 6, the pre-incubation of cells with IT9302 results in a suppressed responsiveness of the CD8+ T cells towards hrIL-10. This

indicates that IT9302 may affect the binding of rhIL-10 to the IL-10 receptor.

EXAMPLE 6

*Suppression of the chemotactic response of CD4+ T lymphocytes
5 towards IL-8*

The experiment was carried out as described in "Leukocyte chemotaxis assay". As shown in Fig. 7, IT9302, in a dose-dependent manner and added to a suspension of human CD4+ T lymphocytes, inhibits the response of the CD4+ T cells to-
10 wards IL-8.

EXAMPLE 7

*Suppression of the chemotactic response of human monocytes
towards MCAF/MCP-1*

The experiment was carried out as described in "Monocyte chemotaxis". As shown in Fig. 8, IT9302, in a dose-dependent manner and added to a suspension of human monocytes, inhibits
15 the chemotactic response of the monocytes towards MCAF/MCP-1.

EXAMPLE 8

*Inhibition of class II MHC molecule expression on human
20 monocytes when stimulated with IFN γ*

In a new experimental model (flow cytometry), it has been shown that monocytes stimulated with IFN- γ upregulate their expression of MHC II antigen, and this induction can be blocked by IL-10 and IT9302 in a similar way. At the same
25 time, both peptides upregulate the number of cells showing apoptosis in the monocytes (see Fig. 12). These experiments indicate that IL-10 and IT9302 can inhibit monocyte/macrophage dependent T cell proliferation by diminishing the anti-

gen presenting capacity of monocytes via the downregulation of Class II MHC expression (see 12).

PMBC's stimulated by PHA start to proliferate as shown by ^3H -thymidine incorporation, which can also be downregulated by IL-10 and IT9302. PHA stimulates T cell proliferation through activation of Ca^{2+} dependent channels. Ca^{2+} fluxes in human T cell clones were diminished when cells were preincubated with IL-10 (Taga, K. et al., 1992). The present experiment shows that T cell proliferation is downregulated by IT9302 also by the control of the Ca^{2+} dependent channels.

Discussion related to the experiments

The present data demonstrate a dose-dependent inhibitory effect of the synthetic nonapeptide, IT9302, on processes which reflect pro-inflammatory activity, including IL-8 production and monocyte and/or T cell migration. Thus, IT9302 was able to suppress the spontaneous production of IL-8 by human monocytes cultured overnight. This could be explained by a direct inhibitory effect on IL-8 mRNA production and/or subsequent protein production and or release. Another mechanism could be explained by the fact that monocytes cultured *in vitro* will express and produce IL-1, which then in turn induces the production of IL-8. This is supported by the fact that it has been demonstrated that IT9302 potently induces the production of IRAP from monocytes. IT9302 may therefore also inhibit spontaneous IL-8 production by interfering with the activity of IL-1. The observed IRAP induction by IT9302 appears to induce a biologically active IRAP, since IT9302 added to the cultures counteracts IL-1-induced IL-8 production, but only when added at least 16 hours before adding IL-1 to the cultures. This could mean that IT9302 inhibits IL-1-induced IL-8 production by inducing the production of IRAP, which then in turn blocks the activity of IL-1 through its receptor. If IT9302 directly inhibited IL-8 production, it would have been expected that addition of IT9302 to the cultures 1 hour before adding IL-1 should inhibit IL-8 pro-

duction, which was not the case (data not shown). Therefore, the observed inhibition of IL-8 production of IT9302 is likely to be due to an induction of IRAP production rather than a direct inhibition of IL-8 production. IT9302 specifically blocks the IL-1 receptor by the induction of IRAP, and thereby the induction of other cytokines which are induced by IL-1, like $\text{TNF}\alpha$, IL-8 and probably many other cytokines and factors. The specificity of the induction was confirmed by that our antibody for IT9302 could block the induction of IRAP. Another IL-10 antibody 19F1 did not block IT9302-induced IRAP production.

IT9302 also mimics IL-10 activity by suppressing the ability of CD4+ T cells to migrate as a response to IL-8. Since IL-8 is related to many different states of inflammation and since CD4+ T cells appear early in the infiltrate of T cell-mediated immune inflammation such as allergy of the skin, this feature may prove to have significant therapeutic value for the control of T cell-mediated immune inflammation.

The demonstrated CD8+ T cell chemotactic activity of IT9302 is also parallel to that of IL-10, and IT9302 may thus activate T cell populations with suppressor activity contributing to the ending of T cell-mediated immune inflammation. Therefore IT9302 according to the examples which are demonstrated above, possesses therapeutic value in diseases where IL-10 and/or IRAP may also have therapeutic value. Additionally, IT9302 may have therapeutic value in diseases where IL-8 and/or MCAF and/or IL-1 are believed to have pathogenetic roles. The present invention describes analogues of IT9302, i.e. substances or peptides having at least some of the above-described properties.

EXAMPLE 9

*Induction of the production of IL-4 in CD4+ T lymphocytes**Background*

Like IL-10, IL-4 is a product of CD4+ T cells of T_H2 type. It was observed that recombinant human IL-10 induces the production of IL-4 by cultured human CD4+ T cells. This means that IL-10, in addition to its own immunosuppressive functions, also induces the production of another immunosuppressive cytokine, IL-4. It was therefore tested whether IT9302 also induces the production of IL-4 by CD4+ T cells.

Thus, CD4+ T cells, purified as described in "Methods for T cell chemotaxis", and cultured as described in the section "Determination of IL-4 production by CD4+ T lymphocytes", were stimulated for 3 days with IT9302 (10 ng/ml) or IL-10 (100 ng/ml). Cytosolic fractions were collected and analyzed for their IL-4 content using Western blotting (Fig. 9) and a goat anti-human IL-4 polyclonal antibody.

As demonstrated in Fig. 9, it was observed that IL-10 as well as IT9302 induce the production of IL-4 by cultured normal human CD4+ T cells.

EXAMPLE 10

Inhibition of the production of TNF- α during a mixed leukocyte reaction (MLR)

It has been demonstrated that the mixed leukocyte reaction is partly dependent on the production of TNF- α during the reaction. It has been shown that IT9302 does not significantly reduce the MLR, but it was found that there is a significant reduction in the production of TNF- α during the MLR.

Thus, MLR was performed by purifying human leukocytes and then culturing 1 million cells/ml from allogeneic donors for 4 days. Before establishing the cultures, one group of cells was irradiated for 2 minutes using beta irradiation. Cyto-
5 solic protein fractions were purified as described in the section "Determination of IL-4 production by CD4+ T lymphocytes", and Western blotting was performed using a rabbit anti-human TNF- α antibody.

As demonstrated in Fig. 10, a significant reduction in the
10 production of TNF- α was observed during a human mixed leukocyte reaction.

EXAMPLE 11

The modulation of the LPS induced shock and leukopenia in swine

15 Since it was found that IT9302 modulates cytokine production, including TNF- α and IL-8, and supported by the published sequence of porcine IL-10 (88), it was tested whether IT9302 was able to modulate the course of LPS induced leukopenia in swine (Fig. 13).

20 In a preliminary experiment, it was tested how the intravenous injection of IT9302 0.1 mg/kg modulated the effect of intravenous injection of 2 μ g/kg LPS in swine (N = 3). IT9302 was injected 30 minutes before injection of LPS, and blood samples were drawn as described in Fig. 13. Total leukocyte
25 count as well as differential cell count were determined, and the total number of neutrophilic leukocytes was calculated on the basis of these results.

As demonstrated, it was observed that injection of LPS caused a transient leukopenia. Injection of IT9302, however, preven-
30 ted leukopenia as demonstrated in the figure.

EXAMPLE 12

The effect of murine IT9302 homologous to human IT9302 on TNF- α release in plasma after LPS administration in mice

It has been demonstrated in animals that recombinant murine IL-10 can protect mice from lethal endotoxemia (89) and in addition, it has been demonstrated that IL-10 administered in humans has inhibitory effects on T-cells and suppresses production of proinflammatory cytokines (90). The aim of the study was to test whether IT9302 can suppress production of TNF- α in mice exposed to endotoxin-induced shock after administration of LPS (Fig. 14).

Eight week old BALB/C mice were used (obtained from Centre for Research Animals, Bomholtgaard, Bomholtvej 10, DK-8680 Ry, Denmark). LPS from *E. coli* was from Sigma (batch 3444114) and murine IT9302 was from Schafer-N, Lersø Parkallé 42, DK-2100 Copenhagen Ø, Denmark.

Mice were injected intraperitoneally with 100 μ g of LPS in 1 ml of 0.9 M NaCl. 60 minutes prior to LPS injection mice were given murine IT9302 equivalent to 0.1 μ g, 1 μ g and 10 μ g of human IL-10. Groups of 5 animals were anaesthetized (Imobilon, Pherrovet, Malmö, Sweden) after 1, 2, 3 and 4 hours, respectively, after which a maximum of whole blood was drawn through cardiac puncture. The blood was centrifuged in the cold and sera were collected and stored at -70°C for subsequent analysis of TNF- α content by ELISA (TNF- α Mouse Immuno Assay Diagnostic kits, Genzyme, Cambridge, MA, USA).

As demonstrated, it was observed that 10 μ g of murine IT9302 clearly suppressed TNF- α in mouse sera compared to the control group not treated with mIT9302 (see Table 3).

TABLE 3

m-TNF- α ng/ml + SEM in serum of mice

Murine IT9302 equivalent to hIL-10 added 60 minutes before
5 LPS

	0	0.1 μ g	1 μ g	10 μ g
1 h	2.48 \pm 0.16	1.92 \pm 0.48	2.64 \pm 0.38	1.84 \pm 0.16
10 2 hs	1.43 \pm 0.17	1.68 \pm 0.27	1.16 \pm 0.21	0.62 \pm 0.14
3 hs	0.48 \pm 0.04	0.05 \pm 0.02	0.18 \pm 0.05	0.0
4 hs	0.09 \pm 0.06	0.06 \pm 0.02	0.20 \pm 0.04	0.05 \pm 0.01

EXAMPLE 13

15 *The modulation of acute pancreatitis induced by bile acid using murine IT9302*

Rodents, mice and rabbits are often used in animal models, and recently Genzyme Diagnostics has advertized with Cross-reactivity Kits for Cytokine Research Products. Especially,
20 it was possible to measure rabbit TNF- α and IFN- γ by mouse Immunoassay Kits. As we were working on a rabbit model, studying the pathophysiological role of IL-8 in experimental acute pancreatitis, we investigated the effect of the murine IT9302 on induced leukopenia (Fig. 14). Our hypothesis was
25 that even IL-10 could be identical in mice and rabbits and might have effects on IL-8-induced leukocyte invasion in the pancreas during acute pancreatitis.

Experimental model

New Zealand white rabbits (*Oryctolagus cuniculus*) weighing
30 1.7-4.0 kg were fasted for 18-24 hours. The operative procedures according to Banerjee et al., 1994 (91) and Hong et al., 1962 (92) were followed, and acute pancreatitis was

induced in rabbits by 5% bile acid given into the pancreatic duct. Murine IT9302 (100 $\mu\text{g/kg}$) was given through a central vein 30 minutes before the bile and subcutaneously in a dose of 100 $\mu\text{g/kg}$ rabbit immediately afterwards. Plasma samples
5 were collected according to Fig. 14.

As demonstrated, it was observed that injection of murine IT9302 into rabbits before induced pancreatitis prevented leukopenia as demonstrated in the Figure.

EXAMPLE 14

10 *The modulation of acute pancreatitis in rabbits induced by bile acid using human IT9302*

The same experimental model was used as in Example 13 with the exception that the murine IT9302 was exchanged by human IT9302. Acute pancreatitis was induced by intraductal injection of 2.0 ml of 5% chemodeoxycholin bile acid (10 animals).
15 Another group of animals was treated with human IT9302 (8 animals), the first dose (100 $\mu\text{g/kg}$) being injected subcutaneously and the second dose (100 $\mu\text{g/ml}$) intravenously, half an hour before the induction of acute pancreatitis. Serum
20 samples were collected for cytokine measurements with time intervals, 0, 1, 3, 6, and 12 hours after the induction of acute pancreatitis.

Methods for the TNF- α and IL-8 measurements in rabbit serum

Genzyme mouse TNF- α ELISA kit code No. 80-3807-00 was used in
25 a modified version for TNF- α measurements in the serum of rabbits. This kit is built up by a solid-phase monoclonal hamster anti-mouse TNF- α antibody which captures the TNF- α present in serum, and a peroxidase-conjugated polyclonal goat anti-mouse TNF- α antibody, substrate and chromagen TMB. The
30 incubation time for serum and standard TNF- α was extended for 4 hours and the development time for substrate incubation was 30 minutes.

Rabbit IL-8 measurements in rabbit serum were carried out by a special IL-8 ELISA kit, a gift from Professor Kouji Matsu-shima, Tokyo, Japan. Briefly, monoclonal anti-IL-8, guinea pig anti-rabbit IL-8 and alkaline phosphatase-conjugated rabbit anti-guinea pig immunoglobulin G antibodies were employed as capture, second and detection antibodies, respectively. For methods, see Ikeda et al. (106).

Result

TABLE 4

Acute pancreatitis in rabbit, by 5% bile acid, content of TNF- α in serum (pg/ml \pm SEM)

0	1	3	6	9	12
1210 \pm 396	1206 \pm 239	1918 \pm 374	1662 \pm 357	1884 \pm 698	915 \pm 431

Acute pancreatitis, treated with human IT9302, 30 minutes before 5% bile acid, content of TNF- α in serum (pg/ml \pm SEM)

0	1	3	6	9	12
347 \pm 77	739 \pm 339	697 \pm 146	658 \pm 156	872 \pm 594	463 \pm 203

TABLE 5

Acute pancreatitis, by 5% bile acid, content of IL-8 in serum (pg/ml \pm SEM)

0	1	3	6	9	12
1154 \pm 351	780 \pm 153	2210 \pm 459	2690 \pm 468	2196 \pm 1058	1833 \pm 1114

Acute pancreatitis, treated with human IT9302, 30 minutes before 5% bile acid, content of IL-8 in serum (pg/ml \pm SEM)

	0	1	3	6	9	12
5	875 \pm 181	695 \pm 205	900 \pm 178	1037 \pm 244	1207 \pm 210	1087 \pm 216

Summary

Maximum TNF- α induction was achieved at 3 hours, and maximum IL-8 at 6 hours. Both TNF- α and IL-8 levels in the blood circulation were markedly downregulated for 0 to 12 hours. The levels of pancreatic enzymes in the blood were also measured (amylase, lipase and tryptase) and they all showed peaks after 3-6 hours after induction of acute pancreatitis, but none of these enzymes appeared to be affected by treatment with IT9302. Histologically similar pancreatic changes were observed in the two groups while there was a significant reduction in interstitial neutrophil infiltration in the lungs.

Conclusion

IT9302 downregulates TNF- α and IL-8 production in a model of bile acid induced acute pancreatitis, and blocks neutrophil infiltration in lungs of these treated rabbits, thereby preventing the development of ARDS-like syndrome in these animals, resulting in a reduction of mortality from 60% to 0% after 12 hours. Interleukin 1 β is regarded as an important inducer of acute pancreatitis (see ref. 107) and thereby supporting our hypothesis that IT9302 can block all IL-1 inducible effects. The reason why human IT9302 can be used in a rabbit model could be explained by the observation made by Dan Gaur et al. and published this year in Nature (108) where he showed that rabbit (Lagomorpha) proteins are phylogentically more close to primates (human) proteins than to other rodents (mouse, rat, ...) proteins.

EXAMPLE 15

IT9302 as a treatment of cancer and in the prevention of metastasis

It was recently demonstrated (111) that systemic administration of cellular IL-10 induces an effective, specific and long-lived immune response against established tumours in mice *in vivo*. It was suggested that this effect is partially explained by the renowned effects of IL-10 on diverse cell types, including co-stimulation of T cell proliferation, chemoattraction of CD8+ T cells, and stimulation of lymphokine-activated killer cell activity. They also observed that human IL-10 can reverse the local immunosuppressive effect of viral IL-10. Another research group confirmed the potential therapeutic role of IL-10 administration in cancer (112) since they observed that IL-10 inhibits metastasis through a natural killer cell-dependent mechanism in an *in vivo* experiment with mice having different tumours, including metastasizing malignant melanoma. Kundu et al. (1996) (113) reported that IL-10 exerts anti-metastatic and anti-tumour effects in a murine model of human breast cancer.

These observations indicate a potential role for human IL-10 and for IT9302 administration in the biological therapy of cancer.

EXAMPLE 16

IT9302 as an immune adjuvant in the treatment of viral infections

IL-10 is known to possess certain anti-viral capacities. Thus, Kollmann et al. (1996) (114) found that IL-10 inhibits acute *in vivo* HIV infection of SCID mice with human fetal thymus and liver. We observed that two of the applicants/-researchers, when applying IT9302 in a cream formulation (total dose 400 to 500 µg) under plastic wrapping occlusion

on the skin of the back for 24 hours, developed an increase in their total number of CD8+ T cells (60% and 90%, respectively) and an increase in serum IRAP concentration from 1 ng/ml to 2 ng/ml. In seven non-treated volunteers, the IRAP concentration never exceeded 1.1 ng/ml. As an accidental and unexpected observation, both researchers observed that common warts (due to cutaneous HPV infection) showed clear signs of inflammation with redness and itching around the warts 3 to 4 days after the application of the IT9302-containing cream. The inflammatory reaction occurred synchronously on several fingers for one of the test persons, while the other person only had one wart on a finger. In both cases the warts quickly and gradually decreased in size during the following 4 to 7 days so that there were no clinical signs of remaining wart infection after 10 to 11 days. At a follow-up control 2 months later, there were no signs of recurrence of the infection.

We therefore find that IT9302, possibly through a systemic activation of NK cells and/or cytotoxic CD8+ T cell activity, is able to evoke a latent immune response against cutaneous HPV infection, eventually resulting in clinical remission of the virus infection. Thus, IT9302 is a possible therapeutic alternative for the treatment of virus infections such as HIV and HPV infections.

EXAMPLE 17

IT9302 as an immune adjuvant in the treatment of inflammatory joint diseases (arthritis)

Anti-IL-1 therapy as well as anti-TNF α therapy appear to have significant clinical potential in the treatment of arthritis (Maini, 1996) (115). As described elsewhere in this document, we have found IT9302 to be an inhibitor of TNF α production as well as a stimulator of IRAP (IL-1 receptor antagonist protein) from human mononuclear cells. Thus, IT9302 is a potential treatment modality of arthritis. This was supported by

an observation of one of the applicants of this invention who, after applying IT9302 (approximately 500 μ g) in a cream basis on the skin for 24 hours, observed a strong reduction in chronic joint pains due to arthritis. This observation was made three times and in each case the symptoms gradually recurred during the following week after removal of the IT9302 application. We are thus finding *in vivo* support of the arguments for using IT9302 in the treatment of acute or chronic inflammatory reactions such as arthritis or other auto-immune diseases.

REFERENCES

1. Bendtzen K. Lymphokines in inflammation. Inflammation Basic Mechanisms Tissue Injuring Principles and Clinical Models (P Venge & A Lindbom eds) 1985; Almqvist & Wiksell International. Stockholm: 187-217.
2. Bendtzen K. Interleukin-1, Interleukin-6, and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett 1988;19:183-192.
3. Larsen C.G. Leukocyte activating and chemotactic cytokines in cell-mediated immune reactions of the human skin. Acta Dermatovenereol. 1991; Suppl. 160:1-48
4. Fiorentino D. F., M. W. Bond, and T. R. Mosmann. 1989. Two types of mouse helper T cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med., 170:2081.
5. Viera P., R. de Wall-Malefyt, M.-N. Dang, K. E. Johnson, R. Kastelein, D. F. Fiorentino, J. E. de Vries, M.-G. Roncarolo, T. R. Mosmann, and K. W. Moore. 1991. Isolation and expression of human cytokine synthesis inhibitory factor (CSIF/IL-10) cDNA clones: homology to Epstein-Barr virus open reading frame BCRF1. Proc. Natl. Acad. Sci. (USA), 88:1172.
6. Moore, K.W., O'Garra A., de Waal Malefyt R., Vieira, Mosmann T.R. 1993. Interleukin-10, Annu Rev. Immunol, 11:165-90.

7. Kim, J.M., Brannan, C.I. Copeland N.G., Jenkins, N.A., Khan, T.A., Moore, K.W. 1992. Structure of the mouse interleukin-10 gene and chromosomal localization of the mouse and human genes. *J. Immunol* 148:3618-23.
- 5 8. Carter, D.B., Deibel, M.R-Jr, Dunn, C.J. et al. 1990. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. *NATURE* 344:633-638.
9. Hannum, C.H., Wilcox, C.J., Arend, W.P. et al. 1990.
10 Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. *Nature* 343:336-40.
10. Firestein, G.S., Boyle, D.L., Yu, C., et al. 1994. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. *Arthritis Rheum* 37:644-652.
15
11. Fisher, C.J.-Jr., Slotman, G.J., Opal, S.M., Pribble, J.P. et al. 1994. Initial evaluation of recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. *The IL-1RA Sepsis Syndrome Study Group. Crit-Care-Med.* 22:12-21.
20
12. de Waal-Malefyt, R., Haanen J., Spits, H., et al. 1991. IL-10 and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II MHC expression. *J. Exp. Med.* 174:915-24.
25
13. Gazzinelli, R.T., Oswald, I.P., James, S.L., Sher, A., 1992. IL-10 inhibits parasite killing and nitric oxide production by IFN- γ -activated macrophages. *J. Immunol.* 148:1792-96.
30
14. Jinquan, T., Larsen, C.G., Gesser, B., Matsushima, K., Thestrup-Pedersen, K. 1993. Human IL-10 is a chemo-attractant for CD8+ T lymphocytes and an inhibitor of IL-8- induced CD4+ T lymphocyte Migration. *Journal of Immunology*, 151:4545-4551.
35
15. Rousset F., E. Garcia, T. Defrance, C. Peronne, D.-H. Hsu, R. Kastelein, K. W. Moore, and J. Banchereau. 1992. IL-10 is a potent growth and differentiation factor for

activated human B lymphocytes. Proc. Natl. Acad. Sci. USA, 175:671.

16. Howard, M., O'Garra, A., Ishida, H., de Waal Malefyt, R., de Vries, J. 1992. Biological properties of Interleukin-10. J. Clin. Immunol 12:239-47.
17. Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K., Muller, W. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-74.
18. Sher, A., Fiorentino, D.F., Caspar, P., Pearce, E., Mosmann, T. 1991. Production of IL-10 by CD4+ lymphocytes correlates with down-regulation of Th1 cytokine synthesis in helminth infection. J. Immunol. 147:2713-16.
19. Clerici, M., Shearer, G.M. 1993 Immunology Today. 14:107-111.
20. Bry, K., Lappalainen, U. 1994. Interleukin-4 and transforming growth factor-beta 1 modulate the production of interleukin-1 receptor antagonist and prostaglandin E2 by decidual cells. Am-J-obstet-Gynecol 170 (4): 1194-1198.
21. Firestein, G., S., Boyle, D. L., Yu, C., Paine, M. M., Whisenand, T. D., Zvaifler, N. J., Arend, W. P. 1994. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis-Rheum, 37/5: 644-652.
22. Roberge, C. J., De-Medicis, R., Dayer, J. M., Rola-Pleszczyński, M., Naccahe, P. H., Poubelle, P. E. 1994. Crystal-induced neutrophil activation: V. Differential production of biologically active IL-1 receptor antagonist. J. Immunol 152/11: 5485-5494.
23. McCall, R. D., Haskill, S., Zimmermann, E. M., Lund, P. K., Thompson, R. C., Sartor, R. B. 1994. Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology (4): 960-72.
25. Kimble, R. B., Vannice, J. L, Bloedow, D. C., Thompson, R. C., Hopfer, W., Kung, V. T., Brownfield, C., Pacifici, R. 1994. Interleukin-1 receptor antagonist de-

creases bone loss and bone resorption in ovariectomized rats. J. Clin Invest. 93/5: 1959-1967

26. Kline, J. N., Geist, L. J., Monick, M. M., Stinski, M. F., Hunninghake, G. W., 1994. J. Immunol. 152 (5): 2351-7
27. Tompkins, R. G. 1994. Human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome (editorial; comment). Crit-Care-Med. 22 (1): 3, 22 (1):12-21
28. Everaerd, B., Brouckaert, P., Fiers, W. 1994. Recombination IL-1 receptor antagonist protects against TNF-induced lethality in mice. J. Immunol. 152/10: 5041-5049
29. Fischer, C. J. Jr., Slotman, G. J., Opal, S. M., Pribble, J. P., Bone, R. C., Emmanuel, G., Ng, D., Bloedow, D. C., Catalano, M. A. 1994. Initial evaluation of human recombination interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group (see comments). Crit-Care-Med. 22(1): 12-21, 22(1): 3
30. Gomez-Reino-Carnoto, J. J. 1994. New therapies in rheumatoid arthritis. Med-Clin 543-545.
32. Nishihara, T., Ohsaki, Y., Ueda, N., Saito, N., Mundy, G. R. 1994. Mouse interleukin-1 receptor antagonist induced by actinobacillus actinomycetemcomitans lipopolysaccharide blocks the effects of interleukin-1 on bone resorption and osteoclast-like cell formation. Infect-Immun. 62(2): 390-7
33. Simon, C., Frances, A., Piquette, G. N., el-Danasouri, I., Zurawski, G., Dang, W., Polan, M. L. 1994. Embryonic implantation in mice is blocked by interleukin-1 receptor antagonist (see comments). Endocrinology. 134(2): 521-8, 134(2): 519-20
34. Baergen, R., Benirschke, K., Ulich, T. R., 1994. Cytokine expression in the placenta. The role of interleukin 1 and interleukin 1 receptor antagonist expres-

sion in chorioamnionitis and parturition. Arch-Pathol-Lab-Med. 118(1): 52-5

35. Tang, W.W., Feng, L., Vannice, J. L., Wilson, C. B. 1994. Interleukin-1 receptor antagonist ameliorates experimental antiglomerular basement membrane antibody-associated glomerulonephritis. J. Clin-Invest. 93(1): 279-9.
36. Cassatella, M. A., Meda, L., Gasperini, S., Calzetti, F., Bonara, S. 1994.
37. Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J. Exp-Med. 179/5: 1695-1699
38. Mancini, R., Bendetti, A., Jezequel, A. M. 1994. An interleukin-1 receptor antagonist decreases fibrosis induced by dimethylnitrosamine in rat liver. Virchows-Arch. 424/1: 25-31
39. Lukacs, N. W., Kunkel, S. L., Burdick, M. D., Lincoln, P. M., Strieter, R. M. 1993.
40. Interleukin-1 receptor antagonist blocks chemokine production in the mixed lymphocyte reaction. Blood. 82(12): 3668-74
41. Bandara, G., Mueller, G. M., Galea-Lauri, J., Tindal, M. H., Georgescu, H. I., Suchanek, M. K., Hung, G. L., Gloriso, J. C., Robbins, P. D., Evans, C. H. 1993.
42. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo transfer. Proc-Natl-Acad-Sci-U-S-A. 90(22): 10764-8
43. Dinarello, C. A. 1994. Anti-interleukin-1 strategies in the treatment of the septic shock syndrome. Can-J-infect-Dis. 5(suppl. A): 9A-16A
44. Oelmann, E., Topp, M. S., Reufi, B., Papadimitriou, C., Koeningsmann, M., Oberberg, D., Thiel, E., Berdel, W. E. 1994. Int-J-Oncol. 4/3: 555-558
45. Estrov, Z. 1993. Interruption of autocrine and paracrine growth-stimulatory mechanisms: a new therapeutic strategy for chronic myelogenous leukemia. Semin-Hematol. 30(3 suppl 3): 35-6

46. Wooley, P.H., Whalen, J.D., Chapman, D.L., Berger, A.E., Richard, K.A., Aspar, D.G., Staite, N.D. 1993. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. *Arthritis Rheum.* 36 (9): 1305-1314
47. Peterson, C.M., Hales, H.A., Hatasaka, H.H., Mitchell, M.D., Rittenhouse, L., Jones, K.P. 1993. Interleukin-1 beta (IL-1 beta) modulates prostaglandin production and the natural IL-1 receptor antagonist inhibits ovulation in the optimally stimulated rat ovarian perfusion model. *Endocrinology* 133 (5): 2301-2306
48. Estrov, Z., Kurzrock, R., Talpaz, M. 1993. Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. *Leuk. Lymphoma* 10 (6): 407-418
49. Chensue, S.W., Bienkowski, M., Eessalu, T.E., Warming-ton, K.S., Hershey, S.D., Lukacs, N.W., Kunkel, S.L. 1993. The IL-1 receptor antagonist protein (IRAP) regulates schistosome egg granuloma formation and the regional lymphoid response. *J. Immunol.* 151 (7): 3654-3662
50. Bowyer, J.F., Davies, D.L., Schmued, L., Broening, H.W., Newport, G.D., Slikker, W Jr., Holson, R.R. 1994. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. *J. Pharmacol. Exp. Ther.* 268/3: 1571-1580
51. Cole, O.F., Sullivan, M.H.F., Elder, M.G. 1993. The 'interleukin-1 receptor antagonist' is a partial agonist of prostaglandin synthesis by human decidual cells. *Prostaglandins* 46/6: 493-498
52. Jenkins, J.K., Arend, W.P. 1993. Interleukin 1 receptor antagonist production in human monocytes is induced by IL-1alpha, IL-3, and IL-4 and GM-CSF. *Cytokine* 5/5: 407-415
53. Coceani, F., Lees, J., Redford, J., Bishai, I. 1992. Interleukin-1 receptor antagonist: effectiveness

against interleukin-1 fever. *Can. J. Pharmacol.* 70
(12): 1590-1596

54. Schiro, R., Longoni, D., Rossi, V., Maglia, O., Doni,
A., Arsura, M., Carrara, G., Maser, G., Vannier, E.,
5 Dinarello, C.A., Rambaldi, A., Biondi, A. 1994. Sup-
pression of juvenile chronic myelogenous leukemia co-
lony growth by interleukin-1 receptor antagonist. *Blood*
83/2: 460-465

55. Watson, M.L., Smith, D., Bourne, A.D., Thompson, R.C.,
10 Westwick, J. 1993. Cytokines contribute to airway dys-
function hyperreactivity, pulmonary eosinophil accumu-
lation and tumor necrosis factor generation by pre-
treatment with an interleukin-1 receptor antagonist.
Am. J. Respir. Cell Mol. Biol. 8 (4): 365-369

56. Abhyankar, S., Gilliland, D.G., Ferrara, J.L.M. 1993.
15 Interleukin-1 is a critical effector molecule during
cytokine dysregulation in graft-versus-host disease to
minor histocompatibility antigens. *Transplantation*
56/6: 1518-1523

57. Lan, H.Y., Nikolic Paterson, D.J., Zarama, M., Vannice,
20 J.L., Atkins, R.C. 1993. Suppression of experimental
crescentic glomerulonephritis by the interleukin-1
receptor antagonist. *Kidney Int.* 43 (2): 479-485

58. Herve, P. 1993. Prevention and treatment of acute GvHD
25 - New modalities. *Nouv. Rev. Fr. Hematol.* 35/3: 295-297

59. Conti, P., Panara, M.R., Barbacane, R.C., Placido,
F.C., Bongrazio, M., Reale, M., Dempsey, R.A., Fiore,
S. 1992. Blocking the interleukin-1 receptor inhibits
leukotriene B4 and prostaglandin E2 generation in human
30 monocyte cultures. *Cell Immunol.* 145 (1): 199-209

60. Kristensen, M., Deleuran, B., Eedy, D.J., Feldmann, M.,
Breathnach, S.M., Brennan, F.M. 1992. Distribution of
interleukin-1 receptor antagonist protein (IRAP),
interleukin-1 receptor, and interleukin-1 alpha in
35 normal and psoriatic skin, Decreased expression of IRAP
in psoriatic lesional epidermis. *Br. J. Dermatol.* 127
(4): 305-311

61. Romero, R., Sepulveda, W., Mazor, M., Brandt, F., Cotton, D.B., Dinarello, C.A., Mitchell, M.D. 1992. The natural interleukin-1 receptor antagonist in term and pre-term parturition. *Am. J. Obstet. Gynecol.* 167 (4 Pt 1): 863-872
62. Dinarello, C.A. 1992. Reduction of inflammation by decreasing production of interleukin-1 or by specific receptor antagonism. *Int. J. Tissue. React.* 14 (2): 65-75
63. Conti, P., Panara, M.R., Barbacane, R.C., Bongrazio, M., Dempsey, R.A., Reale, M. 1993. Human recombinant IL-1 receptor antagonist (IL-1Ra) inhibits leukotriene B4 generation from human monocyte suspensions stimulated by lipopolysaccharide (LPS). *Clin. Exp. Immunol.* 91/3: 526-531
64. DeForge, L.E., Tracey, D.E., Kenney, J.S., Remick, D.G. 1992. Interleukin-1 receptor antagonist protein inhibits interleukin-8 expression in lipopolysaccharide-stimulated human whole blood. *Am. J. Pathol.* 140 (5): 1045-1054
65. Porat, R., Poutsika, D.D., Miller, L.C., Granowitz, E.V., Dinarello, C.A. 1992. Interleukin-1 (IL-1) receptor blockade reduces endotoxin and *Borrelia burgdorferi*-stimulated IL-8 synthesis in human monoclear cells. *Faseb. J.* 6 (7): 2482-2486
66. Boermeester, M.A., van Leeuwen, P.A.M., Schneider, A.J., Houdijk, A.P.J., Ferwerda, C.C., Wesdorp, R.I.C. 1993. Interleukin-1 receptor antagonist: A new therapeutic agent in the treatment of septic syndrome. *Ned. Tijdschr. Geneesks.* 137/7: 337-342
67. Smith, R.J., Chin, J.E., Sam, L.M., Justen, J.M. 1991. Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. *Arthritis Rheum.* 34 (1): 78-83
68. Conti, P., Barbacane, R.C., Panara, M.R., Reale, M., Placido, F.C., Fridas, S., Bongrazio, M., Dempsey, R.A. 1992. Human recombinant interleukin-1 receptor antago-

nist (hrIL-1ra) enhances the stimulatory effect of interleukin-2 on natural killer cell activity against MOLT-4 target cells. *Int. J. Immunopharm.* 14/6: 987-993

69. Selig, W., Tocker, J. 1992. Effect of interleukin-1
5 receptor antagonist on antigen-induced pulmonary
responses in guinea pigs. *Eur. J. Pharmacol.* 213/3:
331-336
70. McCarthy, P.L. Jr., Abhyankar, S., Neben, S., Newman,
G., Sieff, C., Thompson, R.C., Burakoff, S.J., Ferrara,
10 J.L.M. 1991. Inhibition of interleukin-1 by an inter-
leukin-1 receptor antagonist prevents graft-versus-host
diseases. *Blood* 78/8: 1915-1918
71. Estrov, Z, Kurzrock, R., Wetzler, M., Kantarjian, H.,
Blake, M., Harris, D., Gutterman, J.U., Talpaz, M.
15 1991. Suppression of chronic myelogenous leukemia
colony growth by interleukin-1 (IL-1) receptor antago-
nist and soluble IL-1 receptors: A novel application
for inhibitors of IL-1 activity. *Blood* 78/6: 1476-1484
72. Thomas, T.K., Will, P.C., Srivastava, A., Wilson, C.L.,
20 Harbison, M., Little, J., Chesonis, R.S., Pignatello,
M., Schmolze, D., Symington, J., Kilin, P.L., Thompson,
R.C. 1991. Evaluation of an interleukin-1 receptor
antagonist in the rat acetic acid-induced colitis
model. *Agents Actions* 34/1-2: 187-190
- 25 73. Carter, D.B., Deibel, M.R. Jr., Dunn, C.J., Tomich,
C.S.C., Laborde, A.L., Slightom, J.L., Berger, A.E.,
Bienkowski, M.J., Sun, F.F., McEwan, R.N., Harris,
P.K.W., Yem, A.W., Waszak, G.A., Chosay, J.G., Sieu,
L.C., Hardee, M.M., Zurcher Neely, H.A., Reardon, I.M.,
30 Heinrikson, R.L. et al. 1990. Purification, cloning
expression and biological characterization of an inter-
leukin-1 receptor antagonist protein. *Nature* 344/6267:
633-638
74. Larsen C.G, Anderson A.O, Apella E., Oppenheim J.J.,
35 Matsushima K., 1989. *Science* 243:1464;
75. Larsen C.G., Jinqun T., Deleurant B., Thestrup-Peder-
sen K. 1993, IL-10 is a potent regulator of the

chemotactic response of mononuclear cells, but not of granulocytes. *J. Invest. Dermatol.* Vol 100, No 6

76. Sankoff and Kruskal in chapter 1 of "Time Warps, String Edits, and Macromolecules: The Theory and Practice of Sequence Comparison" (Addison-Wesley, Reading, Mass. 1983).
77. Berzofsky, *Science* **229**, (1985) 932-940
78. Bowie et al., *Science* **247**, (1990) 1306-1310
79. Wasserman et al., *J. Immunol.* **87**, 1961, 290-295
80. Levine et al., *Methods in Enzymology* **11**, 1967, 928-936
81. Lewis et al., *Biochemistry* **22**, 1983, 948-954
82. Rene de Waal Maletyt, John Abrahams, Bruce Bennet, Carl G. Figdor and Jan E. de Vries (1991), Interleukin 10 (IL-10) Inhibits Cytokine Synthesis by Human Monocytes: An Autoregulatory Role of IL-10 Produced by Monocytes. *J. Exp. Med.* **174**, 1209-1220
83. Szoka et al., *Ann. Rev. Biophys. Bioeng.* **9**, 1980, 467
84. US Patent No. 4,235,871
85. US 4,501,728
86. US 4,837,028.
87. Walter H. Gotlieb, John S. Abrams, Joanna M. Watson, Thierry J. Velu, Jonathan S. Berek, Otoniel Martinez-Meza (1992), Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. *Cytokine* **4**, No. 5, 385-390
88. Blanche G., P. Gianello, Sh. Germana, M. Baetscher, D.H. Sachs and Chr. LeGuern (1995), Molecular identification of porcine interleukin 10: Regulation of expression in kidney allograft model. *Proc. Natl. Acad. Sci. USA* **92**, 2800-2804
89. Howard, M., T. Muchamuel, S. Andrade, S. Menon (1993), Interleukin 10 protects mice from lethal endotoxemia. *J. Exp. Med.* **177**, 1205-1208
90. Chernoff, A.E., E.V. Granowitz, L. Shapiro, E. Vannier, G. Lonnemann, J.B. Angel, J.S. Kennedy, A.R. Rabson, S. Wolff, C.A. Dinarello (1995), A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory

- cytokine production and immune responses. *J. Immunol.* 154, 5492-5499
91. Banerjee, A.K., S.W. Galloway and A.N. Kingsnorth (1994), Experimental models of acute pancreatitis. *Br. J. Surg.* 81, 1096-1103
92. Hong, S.S., D.S. Chin, T.S. Cho, S.E. Kim (1962), Experimental pancreatitis induced by alcohol and bile in rabbits. *Annals of Surgery* 156(6), 929-939
93. Bodansky, M. (1984), *Principles of Peptide Synthesis*, Springer-Verlag, Berlin
94. Pelton, J.T., et al., *Proc. Natl. Acad. Sci. USA* 82, 233-239
95. Dyson, H., et al. (1988), *Annual Review of Biophysics and Biophysical Chemistry* 17, 305-324).
96. Nakanishi, H., et al. (1993), Peptidomimetics of the immunoglobulin supergene family - a review. *Gene* 137, 51-56
97. US 5,446,128
98. Walter et al. (1995), *Biochemistry* 34, 12118-25
99. Marshall, G.R. (1993), *Tetrahedron* 49, 3547-3558
100. Merrifield, R.B. (1963), *J. Amer. Chem. Soc.* 85, 2149-2154)
101. Kent, S.B.H. (1988), *Annu. Rev. Biochem.* 57, 957-989
102. Carpino, L.A. and Han, G.Y. (1972), *J. Org. Chem.* 37, 3404-3409
103. Stewart, J.M. and Young, J.D. (1983), "Solid Phase Peptide Synthesis", Pierce Chemical Company, Rockford, Illinois
104. Atherton, E. and Sheppard, R.C. (1989), "Solid Phase Peptide Synthesis", IRL Press at Oxford University Press
105. Pennington, M.W. and Dunn, B.M. (eds.) (1994), "Peptide Synthesis Protocols", Humana Press, Totowa, New Jersey
106. Ikeda, N. et al. (1995), *Infection and Immunity*, 4812-4817
107. Fink, G.W. and Norman, J.G. (1996), "Intrapancreatic Interleukin-1 β Gene Expression by Specific Leukocyte

Populations during Acute Pancreatitis", *J. Surgical Research* 63, 369-373

- 5 108. Gaur, D. et al. (1996), "Phylogenetic position of the order Lagomorpha (rabbits, hares and allies)", *Nature*, 379, 333-335
109. Poli, G. et al. (1994), *Proc. Natl. Acad. Sci. USA* 91, 108-112
110. Jensen, I.M. et al. (1993), *Analyt. Cell. Pathol.* 5, 213-223
- 10 111. Berman, R.M., Suzuki, T. et al. (1996), "Systemic administration of cellular IL-10 induces an effective, specific, longlived immune response against established tumors in mice", *J. Immunol.* 157, 231-238
- 15 112. Zheng, L.M., Ojcius, D.M. et al. (1996), "IL-10 inhibits tumor metastasis through an NK cell-dependent mechanism", *J. Exp. Med.* 184, 579-584
113. Kundu, N., Beaty, T.L. et al. (1996), "Antimetastatic and anti-tumor activities of IL-10 in a murine model of breast cancer", *J. Natl. Cancer Inst.* 88, 479-480
- 20 114. Kollmann, T.R., Pettoello-Mantovani, M. et al. (1996), "Inhibition of acute in vivo HIV infection by human IL-10 treatment of SCID mice implanted with human fetal thymus and liver", *Proc. Natl. Acad. Sci. USA* 93, 3126-3131
- 25 115. Maini, R.N. (1996), "A perspective on anti-cytokine and anti T cell directed therapies in rheumatoid arthritis", *Clin. Exp. Rheumatol.* 13, suppl. 12, S35-40

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Steeno Research Group A/S
- (B) STREET: Dunbirkevej 6
- (C) CITY: Odense SV
- (E) COUNTRY: Denmark
- (F) POSTAL CODE (ZIP): 5250

(ii) TITLE OF INVENTION: Immunomodulators

(iii) NUMBER OF SEQUENCES: 23

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Ala Tyr Met Thr Met Lys Ile Arg Asn
1 5

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Ala Tyr Met Thr Ile Lys Met Arg Asn
1 5

(2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Ala Phe Met Thr Leu Lys Leu Arg Asn
1 5

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Ala Tyr Met Thr Met Lys Val Arg Glu
1 5

(2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Gly Tyr Met Thr Met Lys Ile Arg Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids

- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Ala Phe Met Thr Met Lys Ile Arg Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Ala Tyr Ile Thr Met Lys Ile Arg Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Ala Tyr Leu Thr Met Lys Ile Arg Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Ala Tyr Val Thr Met Lys Ile Arg Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Ala Tyr Met Thr Ile Lys Ile Arg Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Ala Tyr Met Thr Leu Lys Ile Arg Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Ala Tyr Met Thr Val Lys Ile Arg Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 13:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Ala Tyr Met Thr Met Lys Ile Arg Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Ala Tyr Met Thr Met Lys Met Arg Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

Ala Tyr Met Thr Met Lys Val Arg Asp
1 5

(2) INFORMATION FOR SEQ ID NO: 16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Ala Tyr Met Thr Met Lys Ile Arg Gln
1 5

(2) INFORMATION FOR SEQ ID NO: 17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Ala Tyr Met Thr Met Lys Ile Arg Glu
1 5

(2) INFORMATION FOR SEQ ID NO: 18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Ser Pro Gly Gln Gly Thr Gln Ser Glu
1 5

(2) INFORMATION FOR SEQ ID NO: 19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids

- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

Thr Xaa Lys Xaa Arg Xaa
1 5

(2) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Xaa Thr Xaa Lys Xaa Arg Xaa
1 5

(2) INFORMATION FOR SEQ ID NO: 21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

Xaa Xaa Thr Xaa Lys Xaa Arg Xaa
1 5

(2) INFORMATION FOR SEQ ID NO: 22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Xaa Xaa Xaa Thr Xaa Lys Xaa Arg Xaa
1 5

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)


(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

GCCTACATGA CAATGAAGAT ACGAAAC

CLAIMS

1. Use of a substance or polypeptide according to the formula



wherein

5 X_1 is Ala or Gly,


X_2 is Tyr or Phe,

X_3 , X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and

10 X_6 is selected from the group consisting of Asn, Asp, Gln and Glu,

optionally at least one of X_1 , X_2 , X_3 , X_4 , X_5 and X_6 is independently substituted with a non-natural or unusual amino acid and/or the peptide is cyclized and/or the peptide is stabilized and/or the amino terminal amino acid residue is acylated and/or the carboxy terminal amino acid residue is amidated, and peptidomimetics modelled on the basis of the
15 above formula for the preparation of a pharmaceutical composition for the reduction of TNF α production.

2. Use of a substance or polypeptide according to the formula



wherein

X_1 is Ala or Gly,

X_2 is Tyr or Phe,

25 X_3 , X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and

X_6 is selected from the group consisting of Asn, Asp, Gln and Glu,

optionally at least one of X_1 , X_2 , X_3 , X_4 , X_5 and X_6 is independently substituted with a non-natural or unusual amino acid and/or the peptide is cyclized and/or the peptide is stabilized and/or the amino terminal amino acid residue is acylated and/or the carboxy terminal amino acid residue is amidated, and peptidomimetics modelled on the basis of the above formula for the preparation of a pharmaceutical composition for the prophylaxis or treatment of pancreatitis.

3. Use of a substance or polypeptide according to the formula

10 X_1 - X_2 - X_3 -Thr- X_4 -Lys- X_5 -Arg- X_6 (SEQ ID NO:22),

wherein

X_1 is Ala or Gly,

X_2 is Tyr or Phe,

15 X_3 , X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and

X_6 is selected from the group consisting of Asn, Asp, Gln and Glu,

optionally at least one of X_1 , X_2 , X_3 , X_4 , X_5 and X_6 is independently substituted with a non-natural or unusual amino acid and/or the peptide is cyclized and/or the peptide is stabilized and/or the amino terminal amino acid residue is acylated and/or the carboxy terminal amino acid residue is amidated, and peptidomimetics modelled on the basis of the above formula for the preparation of a pharmaceutical composition for the prophylaxis or treatment of viral infections such as acquired immun-deficiency syndrom (AIDS) or cutaneous HPV-infection.

4. A substance or polypeptide having the formula

X_1 - X_2 - X_3 -Thr- X_4 -Lys- X_5 -Arg- X_6 (SEQ ID NO:22),

30 wherein

X₁ is Ala or Gly,

X₂ is Tyr or Phe,

X₃, X₄ and X₅ are independently selected from the group consisting of Met, Ile, Leu and Val; and

- 5 X₆ is selected from the group consisting of Asn, Asp, Gln and Glu,

wherein at least one of X₁, X₂, X₃, X₄, X₅ and X₆ is independently substituted with a non-natural or unusual amino acid, said substance or polypeptide having at least one of the
10 following properties

- a) induces inhibition of spontaneous IL-8 production by human monocytes,
- b) induces inhibition of IL-1 β induced IL-8 production by human peripheral blood mononuclear cells (PBMC),
- 15 c) induces production of interleukin-1 receptor antagonistic protein (IRAP) by human monocytes,
- d) induces chemotactic migration of CD8+ human T lymphocytes in vitro,
- e) desensitizes human CD8+ T cells resulting in an unresponsiveness towards rhIL-10,
- 20 f) suppresses the chemotactic response of CD4+ T human lymphocytes towards IL-8,
- g) suppresses the chemotactic response of human monocytes towards MCAF/MCP-1,
- 25 h) inhibits class II MHC molecule expression on human monocytes stimulated by IFN- γ ,
- i) induces the production of IL-4 by cultured normal human CD4+ T cells,
- j) reduces the TNF α production in human mixed leukocyte
30 reaction,
- k) downregulates TNF α and IL-8 production in a rabbit model of bile acid induced acute pancreatitis and reduces neutrophil infiltration in the lungs of the treated rabbits.

5. A substance or polypeptide having the formula

X_2 - X_3 -Thr- X_4 -Lys- X_5 -Arg- X_6 (SEQ ID NO:21),

wherein

X_2 is Tyr or Phe,


X_3 , X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and

X_6 is selected from the group consisting of Asn, Asp, Gln and Glu,

wherein at least one of X_2 , X_3 , X_4 , X_5 and X_6 is independently substituted with a non-natural or unusual amino acid, said substance or polypeptide having at least one of the following properties

- a) induces inhibition of spontaneous IL-8 production by human monocytes,
- b) induces inhibition of IL-1 β induced IL-8 production by human peripheral blood mononuclear cells (PBMC),
- c) induces production of interleukin-1 receptor antagonistic protein (IRAP) by human monocytes,
- d) induces chemotactic migration of CD8+ human T lymphocytes *in vitro*,
- e) desensitizes human CD8+ T cells resulting in an unresponsiveness towards rhIL-10,
- f) suppresses the chemotactic response of CD4+ T human lymphocytes towards IL-8,
- g) suppresses the chemotactic response of human monocytes towards MCAF/MCP-1,
- h) inhibits class II MHC molecule expression on human monocytes stimulated by IFN- γ ,
- i) induces the production of IL-4 by cultured normal human CD4+ T cells,
- j) reduces the TNF α production in human mixed leukocyte reaction,
- k) downregulates TNF α and IL-8 production in a rabbit model of bile acid induced acute pancreatitis and reduces neutrophil infiltration in the lungs of the treated rabbits.

6. A substance or polypeptide having the formula



wherein

- 5 X_3 , X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and
 X_6 is selected from the group consisting of Asn, Asp, Gln and Glu,

wherein at least one of X_3 , X_4 , X_5 and X_6 is independently
10 substituted with a non-natural or unusual amino acid, said substance or polypeptide having at least one of the following properties

- a) induces inhibition of spontaneous IL-8 production by human monocytes,
- 15 b) induces inhibition of IL-1 β induced IL-8 production by human peripheral blood mononuclear cells (PBMC),
- c) induces production of interleukin-1 receptor antagonistic protein (IRAP) by human monocytes,
- d) induces chemotactic migration of CD8+ human T lymphocytes
20 *in vitro*,
- e) desensitizes human CD8+ T cells resulting in an unresponsiveness towards rhIL-10,
- f) suppresses the chemotactic response of CD4+ T human lymphocytes towards IL-8,
- 25 g) suppresses the chemotactic response of human monocytes towards MCAF/MCP-1,
- h) inhibits class II MHC molecule expression on human monocytes stimulated by IFN- γ ,
- i) induces the production of IL-4 by cultured normal human
30 CD4+ T cells,
- j) reduces the TNF α production in human mixed leukocyte reaction,

- k) downregulates TNF α and IL-8 production in a rabbit model of bile acid induced acute pancreatitis and reduces neutrophil infiltration in the lungs of the treated rabbits.

7. A substance or polypeptide having the formula

5 Thr-X₄-Lys-X₅-Arg-X₆ (SEQ ID NO:19),

wherein

X₄ and X₅ are independently selected from the group consisting of Met, Ile, Leu and Val; and

10 X₆ is selected from the group consisting of Asn, Asp, Gln and Glu,

wherein at least one of X₃, X₄, X₅ and X₆ is independently substituted with a non-natural or unusual amino acid, said substance or polypeptide having at least one of the following properties

- 15 a) induces inhibition of spontaneous IL-8 production by human monocytes,
- b) induces inhibition of IL-1 β induced IL-8 production by human peripheral blood mononuclear cells (PBMC),
- c) induces production of interleukin-1 receptor antagonistic
- 20 protein (IRAP) by human monocytes,
- d) induces chemotactic migration of CD8+ human T lymphocytes *in vitro*,
- e) desensitizes human CD8+ T cells resulting in an unresponsiveness towards rhIL-10,
- 25 f) suppresses the chemotactic response of CD4+ T human lymphocytes towards IL-8,
- g) suppresses the chemotactic response of human monocytes towards MCAF/MCP-1,
- h) inhibits class II MHC molecule expression on human monocytes stimulated by IFN- γ ,
- 30 i) induces the production of IL-4 by cultured normal human CD4+ T cells,

- j) reduces the TNF α production in human mixed leukocyte reaction,
k) downregulates TNF α and IL-8 production in a rabbit model of bile acid induced acute pancreatitis and reduces neutrophil infiltration in the lungs of the treated rabbits.

8. A substance or peptide according to any of claims 4-7 which is cyclized.

9. A substance or peptide according to any of claims 4-7 which is stabilized.

10. A substance or peptide according to any of claims 4-7 wherein the amino terminal amino acid residue is acylated.

11. A substance or peptide according to any of claims 4-7 wherein the carboxy terminal amino acid residue is amidated.

12. A peptidomimetic modelled on the basis of the formula

15 $X_1-X_2-X_3\text{-Thr-}X_4\text{-Lys-}X_5\text{-Arg-}X_6$ (SEQ ID NO:22),

wherein

X_1 is Ala or Gly,

X_2 is Tyr or Phe,

20 X_3 , X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and

X_6 is selected from the group consisting of Asn, Asp, Gln and Glu,

said peptidomimetics having at least one of the following properties

- 25 a) induces inhibition of spontaneous IL-8 production by human monocytes,
b) induces inhibition of IL-1 β induced IL-8 production by human peripheral blood mononuclear cells (PBMC),

AMENDED SHEET


- c) induces production of interleukin-1 receptor antagonistic protein (IRAP) by human monocytes,
d) induces chemotactic migration of CD8+ human T lymphocytes in vitro,
5 e) desensitizes human CD8+ T cells resulting in an unresponsiveness towards rhIL-10,
f) suppresses the chemotactic response of CD4+ T human lymphocytes towards IL-8,
g) suppresses the chemotactic response of human monocytes
10 towards MCAF/MCP-1,
h) inhibits class II MHC molecule expression on human monocytes stimulated by IFN- γ ,
i) induces the production of IL-4 by cultured normal human CD4+ T cells,
15 j) reduces the TNF α production in human mixed leukocyte reaction,
k) downregulates TNF α and IL-8 production in a rabbit model of bile acid induced acute pancreatitis and reduces neutrophil infiltration in the lungs of the treated rabbits.
- 20 13. A pharmaceutical composition comprising a substance or polypeptide according to any of claims 4-12.
14. Use of a substance or polypeptide according to any of claims 4-12 for the treatment or prophylaxis of one or more of the diseases mentioned in Tables 1 and 2.
- 25 15. Use of a substance or polypeptide according to claim 4-12 for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of one or more of the diseases mentioned in Tables 1 and 2.
- 30 16. A method of treating and/or preventing one or more of the diseases mentioned in Tables 1 and 2, the method comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a substance or polypeptide according to any of claims 4-12.

END OF SHEET

17. Synthesis of a substance or peptide according to any of claims 4-12 by use of solid-phase peptide synthesis (SPPS), the process comprising the following steps:

- 5 a) covalently coupling the C-terminal amino acid in the form of an N-alfa-protected, optionally side chain-protected reactive derivative, either directly or by means of a suitable linker to a solid support,
- b) removing the N-alfa-protective group,
- 10 c) adding the succeeding protected amino acids according to the desired sequence in a stepwise manner,
- d) removing the side chain-protective groups if any,
- e) upon assembly of the complete peptide chain cleaving the peptide from the resin, and optionally
- 15 f) cyclizing and/or stabilizing the peptide and/or acylating the amino terminal amino acid residue and/or amidating the carboxy terminal amino acid residue.

1/14



IT9302 inhibits spontaneous IL-8 production by purified cultured monocytes. (▲) Indicates the level of IL-8 when using rh IL-10 (100 ng/ml).

Fig. 1

2/14

IT9302 inhibits IL-1 induced (1 ng/ml) IL-8 production by
human peripheral blood mononuclear cells




Fig. 2

3/14

IT9302 stimulated human monocytes





Fig. 3

4/14

IL-10 stimulated human monocytes**Fig. 4**

5/14

Chemotactic activity of IT9302 on CD8+ T cells




Fig. 5

6/14

Desensitization of CD8+ T cells by
IT9302, resulting in unresponsiveness
of CD8+ T cells towards IL-10 (10 ng/ml) induced chemotaxis




Fig. 6

7/14

Suppression of IL-8 activity by IT9302

Effect of IT9302 on IL-8 (10 ng/ml) mediated chemotaxis.




Fig. 7

8/14

IT9302 inhibits MCAF/MCP-1
induced monocyte chemotaxis




Fig. 8

9/14

ECL-Western Blotting of CD4+ T cell cytosolic proteins using a goat anti-human IL-4 antibody.




Stimulation for 3 days with:

1. Control
2. mon.anti-IL-8 antibody WS.4 10 μ g/ml,
3. rIL-8 100 ng/ml,
4. rIL-10 100 ng/ml,
5. IT9302 10 ng/ml,
6. rIFN gamma 10 ng/ml.

Fig. 9

10/14

ECL-Western Blotting of Human Mixed lymphocyte culture cytosolic proteins using a rabbit anti-human TNF- α antibody.



Stimulation for 24 hours with:

1. Control
2. IT9302 10 ng/ml

Fig. 10

11/14

Regulation of T cell proliferation by IL-10 and IT9302





Fig. 11

12/14

HLA-DR expression on human monocytes (Flow-cytometry):



% cells expressing HLA-DR:

36.8

58.4

25.2

31.2

% cells in apoptosis:

6.6

4.1

10.3

9.3

Fig. 12

13/14




Fig. 13

14/14

Leukocyte count in peripheral blood (rabbits)
after induction of acute pancreatitis (5% bile acid)




Fig. 14

Combined Declaration for Patent Application and Power of Attorney

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled (fill in title below)

the specification of which (check one) [] is attached hereto;

- [] was filed in the United States (U.S.) under 35 U.S.C. §111 on _____, as USSN _____*; or
 [X] was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/DK97/00021, filed 16 January 1997, entry requested and basic filing fee paid on _____*; national stage application received USSN _____*; §371/§102(e) date _____* (*if known),

and was amended on _____ (if applicable).

(include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above; and that I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 C.F.R. § 1.56(a).

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119, 365 of any prior foreign application(s) for patent or inventor's certificate, or prior PCT application(s) designating a country other than the U.S., listed below with the "Yes" box checked and have also identified below any such application having a filing date before that of the application on which priority is claimed:

PCT/DK96/00029	PCT	18 January 1996	[X] YES	[] NO	(Check One)
(Number)	(Country)	(Day Month Year Filed)			
_____	_____	_____	[] YES	[] NO	(Check One)
(Number)	(Country)	(Day Month Year Filed)			

I hereby claim the benefit under 35 U.S.C. § 120 of any prior U.S. Application(s) or prior PCT Application(s) designating the U.S. listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as defined in 37 C.F.R., §1.56(a) which occurred between the filing date of the prior application and the national filing date of this application:

(Application Serial No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)
_____	_____	_____
(Application Serial No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)
_____	_____	_____

I hereby appoint the following attorneys, with full power of substitution, association, and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

SHERIDAN NEIMARK, REG. NO. 20,520	-	ROGER L. BROMDY, REG. NO. 25,618	-	ANNE M. KORNBAU, REG. NO. 25,884
NORMAN J. LATKER, REG. NO. 19,963	-	IVER P. COOPER, REG. NO. 28,005	-	A. FRED STAROBIN, REG. NO. 18,453
ALLEN C. YUN, REG. NO. 37,971*	-	NICK S. BROMER, REG. NO. 33,478*	-	* Patent Agent



ADDRESS ALL CORRESPONDENCE TO:

BROMDY AND NEIMARK
 419 Seventh Street, N.W., Suite 300
 Washington, D.C. 20004

DIRECT ALL TELEPHONE CALLS TO:

BROMDY AND NEIMARK
 (202) 628-5197

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST OR SOLE INVENTOR (capitalize surname) <u>Christian Grønhoj LARSEN</u>		INVENTOR'S SIGNATURE 	DATE <u>18.6.98</u>
RESIDENCE (city, state, if U.S.; city, country, if foreign) <u>Aarhus, Denmark</u>		CITIZEN OF <u>Denmark</u>	
POST OFFICE ADDRESS (usually the home address; include postal code and country) <u>Kildegården 1, 3.tv., DK-8000 Aarhus C, Denmark</u>			
FULL NAME OF ADDITIONAL INVENTOR <u>Borbala GESSER</u>		INVENTOR'S SIGNATURE 	DATE <u>18.6.98</u>
RESIDENCE <u>Hasselager, Denmark</u>		CITIZEN OF <u>Sweden</u>	
POST OFFICE ADDRESS <u>Pilegårdsvej 233, Kolt, DK-8361 Hasselager, Denmark</u>			